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Preface 
Leukemia is responsible for the majority of cancer-related deaths among people 
under the age of 20 [1]. A subset of particularly aggressive leukemias carry 
genomic rearrangements of the Mixed Lineage Leukemia (MLL) gene, and these 
leukemias are generally associated with poor clinical outcome [2]. MLL 
rearrangements are mainly found in the form of internal gene amplifications and 
chromosomal translocations, which result in the in-frame fusion of the N-terminus 
of MLL with one of a variety of different fusion partners. Although significant 
progress has been made towards understanding how different domains of MLL 
and its fusion partners contribute to leukemogenesis, there is still much to 
understand in order to effectively treat patients that are afflicted with MLL 
rearrangements. The aim of this project was to further elucidate the mechanisms 
of MLL fusion protein-mediated leukemogenesis with a focus on the contribution 
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Abstract 
Leukemogenic MLL fusion proteins, including MLL-AF4, MLL-AF9, and MLL-ENL, 
transform through up regulated expression of HOX genes and the HOX cofactor MEIS1. 
How they lead to the aberrant activation of these genes is not completely understood. In 
this study, we identified proteins recruited by one of the most common MLL fusion 
proteins, MLL-AF9, through purification of proteins that interact with the transforming 
domain of AF9 in myeloblastic M1 cells. Consistent with earlier purifications of ENL and 
AF4 from 293 cells, the 90 amino acid C-terminal domain associates with many of the 
most common MLL translocation partners including Enl, Af4, Laf4, Af5q31 and Af10. 
This complex, previously termed EAP for Elongation Assisting Proteins, contains the 
RNA polymerase II C-terminal domain kinase Cdk9/Cyclin T1/T2 (pTEFb), the histone 
H3 lysine 79 methyltransferase Dot1l, and the Polycomb proteins Pc3 and Ring1b. 
Chromatin immunoprecipitation (ChIP) studies show that myeloid cells transformed by 
MLL fusion proteins show higher levels and a broader distribution of EAP components 
at leukemogenic loci. Inhibition of EAP components pTEFb and Dot1l show that both 
contribute significantly to activation of Hoxa9 and Meis1 expression. EAP is dynamically 
associated with the Hoxa9 and Meis1 loci in hematopoietic cells and rapidly dissociates 
during induction of differentiation. However, in the presence of MLL fusion proteins, 
EAP dissociation from target loci is prevented. These data suggest that MLL fusion 
proteins deregulate key target genes by excessive recruitment and impaired 




Chromatin Structure in the Regulation of Transcription 
DNA is spooled around histone octamers, known as nucleosomes, which 
contain two copies of histone 2A, 2B, 3, and 4 [3]. Nucleosomal structure is 
modified in different ways in order to compact or loosen DNA during 
transcriptional repression or activation, respectively. It may be altered through 
ATP-dependent processes, such as nucleosome sliding, eviction, and histone 
dimer exchange [4], or through post-translational modifications (PTMs) of the 
protruding histone tails and globular domain [5].  
The level of transcriptional control conferred by the structure of chromatin 
accounts for how cells with the same DNA sequence can form complex 
organisms. It has also become clear over the past decade that the aberrant 
regulation of chromatin remodeling processes has critical roles in the 
development of cancer and many other pathological conditions [6,7,8,9,10,11]. 
There are several different enzymes that act on histones, including methyl 
transferases, kinases, ubiquitin ligases, and acetylases, and their activities serve 
as indicators of transcriptional status [5]. For instance, histone acetylation is 
generally associated with transcriptional activation, while histone deacetylation is 
associated with transcriptional repression. Histone lysine methyl transferases 
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(HLMTs), which are the primary focus of the work presented herein, methylate 
specific residues on histones. Histone methylation marks are associated with 
expressed or silenced genes, depending on which residue is methylated [5]. 
Mixed Lineage Leukemia is among the HLMTs, with many other roles in 
regulating chromatin structure.  
Mixed Lineage Leukemia 
Mixed Lineage Leukemia (MLL) is a 3,969 amino acid transcription factor 
that has multiple functional domains (Fig. 1). At its N-terminus, MLL has DNA 
binding domains, including three AT hooks and a DNA methyl transferase 
homology region that binds unmethylated DNA [12,13] and transcriptional 
repressors such as Bmi1, histone deacetylases (HDACs) 1 and 2, and C-terminal 
Binding Protein (CtBP) [14]. Downstream are three canonical plant 
homeodomain (PHD) fingers, a bromodomain, and one extended PHD. PHD3 of 
MLL binds trimethylated lysine 4 of histone 3 (H3K4me3) [15] as well as the 
transcriptionally repressive proline isomerase Cyp33 [16,17]. Downstream is a 
transcriptional transactivation domain that interacts with the acetyl transferase 
Creb-binding protein (CBP) [18]. The C-terminus interacts with the histone acetyl 
transferase (HAT) MOF, which acetylates lysine 16 of histone 4 to activate 
transcription [19]. MLL has a highly conserved SET domain at its C-terminus that 
confers MLL with an enzymatic ability to methylate the lysine 4 residue of histone 
3 (H3K4) [20]. The SET domain also interacts with INI1, a component of the 
SWI/SNF chromatin remodeling complex [21]. The SWI/SNF complex is 
comprised of 8 to14 subunits, with the ATPase BRG1 or hBRM at its core [22]. 
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Although BRG1 and hBRM are sufficient to disrupt nucleosomal structure,
associating proteins such as INI1 enhance their enzymatic activity and contribute 




Figure 1 Schematic of wild-type MLL protein 
 
Although there are reports that MLL represses transcription through its 
DNMT domain and third PHD finger [16,23,24,25,26], it is largely characterized 
as a transcriptional activator. In fact, the DNMT domain and third PHD finger also 
have roles in MLL-mediated transcriptional activation [13,15]. MLL regulates the 
expression of many genes, but some of the most notable in the context of both 
embryonic development and leukemogenesis are Hox genes and Hox cofactors 
[20,27,28].  
HOX genes 
HOX genes encode a conserved family of transcription factors that are 
critical in axis specification during embryonic development [29]. In mammalian 
cells, they exist in four clusters, A, B, C, and D, on four different chromosomes. 
HOX proteins contain homeodomains that bind DNA with poor sequence 
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specificity; further DNA specificity is conferred by their cofactors MEIS and PBX, 
which also have homeodomains. HOX proteins can activate or repress 
transcription, depending on the ternary structure that is created with its cofactors 
and DNA [30]. They also bind DNA replication origins and are thought to be 
involved in the deregulation of DNA replication in cancers [31]. 
The A cluster HOX genes such as HOXA7, HOXA9, and HOXA10 are 
over-expressed in many cases of acute leukemia, and HOXA over-expression is 
a poor prognostic factor [32,33,34]. Normally, the expression of these genes is 
tightly controlled at the transcriptional, post-transcriptional, and post-translational 
levels. They are highly transcribed in primitive hematopoietic cells, and 
transcription levels decrease with differentiation [29]. HOX transcripts are 
targeted by microRNAs [35], and the proteins are subjected to proteasomal 
degradation [36] and post-translational modifications that modulate DNA binding 
[37,38]. The necessity for all these layers of regulation may be explained by the 
potency of these proteins, which is demonstrated by the fact that over-expression 
of Hoxa9 and its cofactor, Meis1, is sufficient to transform hematopoietic cells 
and lead to leukemia in mice [39]. The combination of Hoxa9 and Meis1 induces 
a stem-cell like gene expression program that enhances proliferation and 
imposes a differentiation block [39,40,41]. 
 Mll and Hox gene expression 
The importance of Mll in regulating Hox expression is demonstrated in Mll-
knockout mice [28]. Homozygous mice die at day ten of embryogenesis, and 
heterozygous mice display skeletal and hematopoietic defects. These 
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phenotypes are associated with severe deficiencies in Hox expression. 
Subsequent studies have shown that MLL directly binds to the Hox and Meis loci 
and activates their transcription through its methyl transferase activity [20]. 
Mice expressing truncated Mll, which lacks the SET domain and hence its 
methyl transferase activity display a phenotype mildly reminiscent of the Mll 
knockout mice [42]. These mice are viable, with slight skeletal malformations. 
They have decreased Hox expression that correlates with decreases in H3K4 
monomethylation and increases in DNA methylation at their loci. Thus, while the 
methyl transferase domain of MLL is important for transcription, it is dispensable 
for viability. Not surprisingly, MLL has roles beyond its methyl transferase activity 
that are critical to survival.  
MLL fusion proteins in leukemia 
Rearrangements of the MLL gene in the form of translocations is found in 
up to 10% of human leukemia cases. These events are associated with acute 
lymphocytic, myeloid, and therapy-related leukemias that generally have a poor 
prognosis [2,43]. The translocations lead to the production of an in-frame fusion 
protein where a small portion of the N-terminus of MLL is fused to one of over 
fifty possible fusion partners. The most common fusion proteins are MLL-AF4, 
MLL-AF9, and MLL-ENL. Knock-in murine and other transformation models have 
shown that all three of these fusion proteins are leukemogenic, with characteristic 
over-expression of Hox genes [44,45,46,47,48,49,50]. This accurately portrays 
the human disease, where leukemias carrying MLL fusions have distinctly high 
levels of HOX and the HOX cofactor MEIS1 [51]. Furthermore, Hoxa9 and Meis1 
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are essential for leukemic transformation by MLL-AF9 and MLL-ENL in murine 
leukemogenesis assays [52], and HOXA9 is also critical to human leukemia cell 
lines that carry these translocations [40]. 
There are many interesting aspects of MLL fusion proteins that contribute 
to transformation. The N-terminus interacts with menin and the polymerase 
associated factor complex (PAFc). These interactions are important for targeting 
MLL and MLL fusion proteins to genes and for MLL fusion protein-mediated 
leukemogenesis [53,54,55,56,57]. Menin, originally identified as a tumor 
suppressor in multiple endocrine neoplasias [58] also recruits LEDGF, a 
chromatin-associating protein with roles in transcriptional activation [54]. PAFc, 
which is composed of five subunits, has roles in both the initiation and elongation 
stages of RNA polymerase II activity [59]. PAFc is critical for histone 2B 
monoubiquitination, which is a prerequisite for H3K4 and H3K79 methylation 
[60,61,62]. The DNMT domain of N-terminal MLL has been shown to bind CpG 
rich regions in DNA, physically protecting Hox genes from DNA methylation-
mediated gene silencing [13]. The C-terminal fusion partners have little homology 
between each other but have been grouped into two categories: nuclear and 
cytoplasmic partners. 
The cytoplasmic partners, such as AF1p and GAS7, are found only in a 
minority of MLL rearrangements. These proteins, which do not have known 
nuclear functions, appear to cause dimerization of the fusion protein, which is 
sufficient to cause leukemic transformation [63,64]. The dimerization-based 
mode of transformation is illustrated in a transgenic mouse that expresses MLL 
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fused to beta-galactosidase, an arbitrary, tetramerizing protein, and develops 
leukemia [65]. However, dimerization-based leukemia has a long latency and low 
penetrance compared to leukemia induced by MLL fusions with nuclear partners. 
The nuclear fusion partners, AF4, AF9, and ENL are by far the most 
common and are transcriptional activators [66,67,68]. MLL-ENL and MLL-AF9 
have been shown to require the transactivation domains of their respective 
partners for transformation [66]. These fusion proteins result in acute lymphocytic 
and myeloid leukemias that develop within three months, with most mice 
succumbing to the disease within a year [44,46].  
MLL fusion proteins bind across transcriptionally active genes and are 
associated with chromatin modifications indicative of active transcription, such as 
H3 and H4 acetylation, H3K4 methylation, and H3K79 methylation [69]. These 
marks are induced by the dimerization and transactivation-based modes of 
transcription. However, MLL fusion proteins do not possess the transactivation 
and SET domains of wild-type MLL that are associated with some of these 
chromatin modifications. The following studies explored whether these domains 
are important to MLL fusion protein activity and how MLL fusion proteins 








The Role of Wildtype Mll in MLL Fusion Protein-Mediated Leukemogenesis 
Introduction 
Both MLL fusion proteins and wild-type MLL function as transcriptional 
activators of Hox expression. In almost all cases of leukemia with MLL 
translocations, the expression of wild-type MLL is retained. In fact, increased 
levels of wild-type Mll co-localize with MLL fusions at target genes such as 
Hoxa9 and Meis1 [69]. This suggests that wild-type MLL may have a role in MLL 
fusion-mediated leukemogenesis. Wild-type MLL has H3K4 methyltransferase 
activity through its SET domain [20] as well as the ability to interact with the 
HATs CBP and MOF [19], and these activities are associated with transcriptional 
activation of Hox genes. MLL fusion proteins have lost these domains in the 
translocation event. Thus, one possibility is that wild-type Mll is critical to MLL 
fusion protein-induced transformation through its HAT and HMT functions. 
Another possibility is that MLL fusion proteins implement alternative mechanisms 
to recruit HMT, HAT, or other chromatin modifying-activities. We first explored 
the role of wild-type Mll in MLL-AF9-transformed myeloblasts, and in our 
experimental system, found that loss of wild-type Mll does not have a discernable 
effect on the phenotype of MLL-AF9 transformed cells.
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Materials and Methods 
Cell Lines MLL-AF9 and HOXA9/MEIS1 transformed myeloblast cell lines that 
have exons three and four of both Mll alleles flanked by loxp sites (Fig. 2.1, Mll-
loxp cells from Patricia Ernst) were obtained from Mary Ellen Martin in Jay 
Hess’s lab (UPenn).  
            
Figure 2.1 Schematic of floxed Mll alleles Red arrows indicate primers used for 
genotyping. Size of amplified fragment is indicated below. 
 
MSCV-Cre-ER-puro (from Charles Roberts) was packaged into retrovirus using 
the Plat-E cell line. The Mll-floxed hematopoietic progenitor cells were then 
transduced by spinoculation with Cre-ER retrovirus for 90 minutes at 2500 RPM, 
25 C in an Eppendorf 5810 R centrifuge. MLL-AF9, Cre-ER transduced cells 
were selected with 625 nM puromycin and then single-cell sorted to obtain 
monoclonal cell lines. HOXA9/MEIS1, Cre-ER transduced cells were single cell 
sorted and screened by genotyping (see below) after 4-hydroxytamoxifen 
treatment, as MEIS1 is in the MSCV-puro vector. MLL-AF9 and HOXA9/MEIS1 
transformed cells were treated with 25 nM and 100 nM 4-hydroxytamoxifen 
(Sigma), respectively, in order to activate Cre recombinase. All cells were grown 
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in IMDM (Invitrogen) with 15% FBS (Stem Cell Technologies) and 10 ng/mL IL-3. 
293 cells were maintained in DMEM with 10% FBS. 
Genotyping Primers used for detection of Mll after Cre-mediated excised are 5’-
GATTGGCCAATGTCTCGTAGTAGGC-3’ (forward) and 5’-
CAGTGGACATTCCAACTCTTCAA-3’ (reverse). Primers used for detection of in 
tact Mll use the same forward primer, but the reverse primer 5’-
CACCCAGCATTGCAGAGTCAG-3’. All three primers were used in the same 
PCR reaction using an annealing temperature of 58 C. Products were run on 3% 
agarose (Invitrogen) gels and visualized with ethidium bromide. 
Chromatin Immunoprecipitation Chromatin immunoprecipitation (ChIP) was 
performed according to Upstate’s protocol using their recommended lysis, 
dilution, and wash buffers. In brief, cells were fixed in 1% formaldehyde for 15 
minutes at room temperature. Cells were pelleted, PBS-rinsed, and snap frozen. 
After thawing, cells were lysed and sonicated at high intensity 30 second on-off 
cycles for 15 minutes in the Diagenode Bioruptor XL. These conditions generated 
an average DNA fragment size of 500 bp as determined by DNA electrophoresis. 
Protein-DNA complexes were collected using anti-MLLC (from Yali Dou), anti-
trimethyl-H3K4 (Millipore, 04-745), or anti-AF9 (Bethyl, A300-597A)-conjugated 
Protein G Dynabeads. After washing the beads, DNA was eluted by incubation 
with SDS buffer (1% SDS, 100 mM sodium bicarbonate) for 30 minutes at 42ºC. 
DNA-protein cross-links were reversed overnight in 0.2 M NaCl at 65 C. DNA 
was purified using the QIAquick PCR Purification Kit (Qiagen) and subjected to 
qPCR. 
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Morphology Staining After 4-hydroxytamoxifen treatment, cells were stained 
with HEMA-3 stain kit (Fisher Scientific) according to the manufacturer’s 
instructions. 
Cell Growth Cells were seeded at a density of 105 cells/mL in 8 mL of growth 
media and counted each day using Trypan blue (Invitrogen) exclusion. 
Flow Cytometric Analysis Cells were harvested, washed with PBS, and stained 
for 30 minutes with anti-c-Kit-FITC (BD Pharmingen), anti-Mac1-PE, and anti-Gr-
1-FITC (BD Pharmingen. Cells were washed with PBS two times, filtered into 
flow cytometry polystyrene tubes with strainer caps, and flow cytometry was 
performed at the University of Michigan Flow Cytometry Core. Data were 
analyzed using WinList 3.0 software. 
qPCR Hoxa9 and Meis1 expression and ChIPed DNA were detected using 
Taqman primers (Applied Biosystems) using Applied Biosystems 7500 Real-
Time PCR system. Expression was normalized to Gapdh (Applied Biosystems). 
and analyzed using the ∆Ct method [70]. Data is expressed as percent of total 
input using the formula  % Total Input = 2^-[Ct (IP)-Ct (Input)] [71]. Primer and 





































































































Disruption of wild-type Mll 
 Conditional Mll knock-out cells that have exons three and four of both Mll 
alleles flanked by loxp sites (Fig. 2.1) have previously been utilized to study the 
role of wild-type Mll in normal hematopoeisis [27,72]. After Cre recombinase-
mediated excision of exons three and four of Mll, the gene encodes a 
hypomorphic Mll protein that lacks 1000 residues at the N-terminus, including the 
AT hooks and subnuclear and nuclear targeting motifs. Hematopoietic cells with 
Mll disrupted by this method have reductions in Hox expression and lose the 
ability to reconstitute blood and bone marrow in recipient mice. 
We transformed hematopoietic progenitor cells isolated from these 
conditional Mll-/- mice with MLL-AF9 or a combination of HOXA9 and MEIS1 to 
test the importance and specificity of wild-type Mll to MLL fusion protein-
mediated leukemic transformation. Complete excision of wild-type Mll could not 
be achieved in the polyclonal pool of drug-selected Cre-ER positive cells. Thus, 
four monoclonal cell lines stably expressing Cre-ER were established and treated 
with 4-hydroxytamoxifen. To follow Cre activity, the cells were genotyped after 
ethanol or 4-hydroxytamoxifen treatment using PCR primers that amplify in tact 
or disrupted Mll (Fig. 2.1). In the HOXA9/MEIS1 transformed cells, complete 
excision of Mll was detected after 24 hours of treatment with 100 nM 4-
hydroxytamoxifen (Fig. 2.2, bottom). Non-floxed MLL-AF9 transformed cells were 
sensitive to the toxicity of 4-hydroxytamoxifen, and complete disruption of Mll in 
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these cells was achieved after five days of treatment with 25 nM 4-
hydroxytamoxifen (Fig. 2.2, top). 
                      
Figure 2.2 Genotyping results after 4-hydroxytamoxifen treatment Monoclonal 
MLL-AF9-transformed (top) or Hoxa9/Meis1-transformed (bottom) cell lines 
treated with ethanol (-) or 4-hydroxytamoxifen (+). 
  
To ensure that Mll disruption resulted in loss of functional Mll protein, 
chromatin immunoprecipation (ChIP) followed by q-PCR was performed to detect 
wild-type Mll and its associated chromatin modification, H3K4 trimethylation, at 
target loci in MLL-AF9 transformed cells (Fig. 2.3). In cells with the wild-type Mll 
alleles disrupted, a three-fold reduction of Mll binding was observed at the Hoxa9 
locus. However, no changes in H3K4 trimethylation were seen after two weeks of 
excision. 
Using an AF9 antibody that recognizes both endogenous Af9 and MLL-
AF9, we looked at binding of AF9 and MLL-AF9 after Mll disruption (Fig. 2.4). 
Interestingly, a decrease in binding by one or both of these proteins was 
detected, suggesting there may be a link between wild-type Mll and the fusion 
protein and/or the fusion partner.  
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Figure 2.3 Effects of Mll disruption on Mll and H3K4 trimethylation levels at 
Hoxa9 ChIP-qPCR for Mll (left) and H3K4 trimethylation in Mll+/+ and Mll-/- cells. 
Schematics of Hoxa9 are depicted below the graphs, with red arrows indicating 
transcription start sites and black boxes indicating exons. HD is the 
homeodomain-encoding exon. This experiment was performed once.  
 
 
                
Figure 2.4 Effects of Mll disruption on Af9 at Hoxa9 ChIP-qPCR for Af9 at Hoxa9 
in Mll+/+ and Mll-/- cells Schematics of Hoxa9 are depicted below the graphs, 
with red arrows indicating transcription start sites and black boxes indicating 
exons. HD is the homeodomain-encoding exon. This experiment was performed 
once.                 
 
 We also looked at another target of Mll, Meis1, and similar results were 
observed, with decreases in Mll and Af9 binding, but no change in H3K4 
trimethylation (Fig. 2.5). 
 16 
  
                            
Figure 2.5 Mll-C, Af9, and trimethylated H3K4 levels at Meis1 ChIP-qPCR in the 
coding region of Meis1 in Mll+/+ and Mll-/- cells. Antibodies used for ChIP are 
indicated below the graph. This experiment was performed once. 
 
MLL-AF9 transformed cells do not require wild-type MLL 
 Both the HOXA9/MEIS1 and MLL-AF9 transformed cells continued to 
grow in the presence of 4-hydroxytamoxifen, and a dramatic effect of disrupting 
wild-type Mll was not observed. However, we continued to analyze the cells to 
determine whether loss of wild-type MLL had an effect on any aspect of the 
leukemic phenotype. The morphology, growth, cell surface markers, and gene 
expression levels of cells with and without functional wild-type Mll were 
compared in four monoclonal cell lines. As shown below in representative 
experiments, no significant differences were observed in the morphology, growth, 
immunophenotype, or gene expression of the monoclonal cell lines after Mll 
disruption (Fig. 2.6A-D). The only exception was an increased expression of 
Meis1 found in Clone 1 (Fig. 2.6, right). Since this was not observed in the other 
three clones, it is thought to be a quirk of Clone 1 rather than a representative 
result of Mll loss.  
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Figure 2.6 Effects of wild-type Mll disruption in MLL-AF9 transformed cells A) 
Wright-Giemsa stained cell with (left) or lacking (right) functional wild-type Mll. B) 
Growth curves of MLL-AF9 transformed cells with Mll-/-or Mll+/+. C) 
Immunophenotype after Mll disruption. Red graphs are isotype controls. Black 
graphs represent Mll+/+ cells. Green graphs represent Mll-/- cells. D) Hoxa9 (left) 
and Meis1 (right) expression in four monoclonal cells lines or the polyclonal pool 











According to these experiments, disrupting wild-type Mll function does not 
have a significant effect on leukemic myeloblasts. However, Thiel et al. recently 
published that wild-type Mll is needed for MLL fusion protein-mediated 
leukemogenesis [57]. This was concluded based on the same conditional knock-
out cells used here and knock-down experiments in murine and human leukemia 
cells. Another recent report suggests that wild-type MLL is needed for MLL fusion 
protein binding to target loci [73].  
The most likely explanation for the discrepancy between our results and 
those of other groups is that the monoclonal cell lines used in our experiments 
represent a fraction of cells that have acquired additional genetic events that 
contribute to transformation. Even though dramatic reductions in wild-type Mll 
binding were observed after Mll excision, no changes in H3K4 trimethylation 
were detected. This is in contrast to the study by Thiel et al. where decreases in 
di and trimethylated H3K4 were observed after shRNA-mediated knockdown of 
MLL in the human leukemia THP-1 cell line, which expresses MLL-AF9. Thus, 
the monoclonal cell lines utilized in this study may have found ways to adapt, for 
example, by recruiting another H3K4 methyl transferase, or although unlikely 
given the half-life of wild-type MLL [74,75], residual wild-type Mll protein may be 
stabilized by the MLL fusion protein or some other mechanism. Of note, one 
acute myeloid leukemia cell line with the MLL-AF6 translocation lacks expression 
of the other MLL allele [76].  
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In retrospect, it appears that the polyclonal cell line may indicate a role of 
wild-type Mll in MLL-AF9 mediated-leukemic transformation as Hoxa9 levels 
decreased to approximately 60% after Mll disruption (Fig. 2.6D). These cells 
were not used for further study since complete excision of wild-type MLL could 
not be achieved, again perhaps indicating the importance of wild-type Mll to 
many of the cells. Testing the leukemogenicity of polyclonal and monoclonal 
MLL-AF9-transformed Mll+/+ and Mll-/- cells by transplantation in irradiated mice 
may reconcile our data with those of Thiel et al. 
Based on the results of these initial experiments, we focused our efforts 
on identifying what additional proteins and activities are recruited by one of the 
most common MLL translocation partners, AF9.
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Chapter 3 
The Role of the Fusion Partner in MLL Fusion Protein-Mediated 
Leukemogenesis 
Introduction 
AF4, AF9, and ENL 
 AF9 and ENL share 80% sequence homology and further structural 
homology in their C-terminal transactivation domains that is critical to gene 
activation [66]. The 90 C-terminal amino acids of AF9 and ENL are sufficient and 
necessary for leukemic transformation when fused to the N-terminus of MLL 
[44,82]. Through two-hybrid, GST pull-down, and overexpression systems, AF4, 
AF5q31, and PC3 have been shown to interact with these 90 residues. ENL also 
binds histone 1 and histone 3 through its N-terminal YEATS domain, which is 
shared with AF9 [77,78,79].   
AF4, AF5q31, and LAF4 are members of the fragile X mental retardation 
(FMR2) family of proteins, all four of which have been identified as MLL fusion 
partners in leukemia. These proteins have three characterized domains, 
including a DNA binding domain at the N-terminus, a transactivation domain, and 
a conserved C-terminal domain [80]. Early studies revealed that AF4 colocalizes 
with AF9 in leukemia cells, and although the MLL-AF4 fusion protein maintains 
this association, it alters the subnuclear localization of AF9 [81]. Altogether, these 
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initial experiments suggested a mechanistic link between the various MLL fusion 
proteins in leukemia.  
In this study, we focused on defining the mechanisms of transactivation by 
one of the most common MLL fusion proteins, MLL-AF9, and explored possible 
therapeutic targets. We first identified proteins that interact with the C-terminal 90 
amino acids of AF9, the minimal domain required for transformation when fused 
to the N-terminal fragment of MLL [44,82]. We found that, in myeloblastic cells, a 
complex that includes several other MLL fusion partners and key transcriptional 
regulators associates with the transforming domain of AF9 and the MLL-AF9 
fusion protein. These proteins have been named Elongation Assisting Proteins 
(EAP). ChIP studies for EAP components show that they are localized to 
leukemogenic genes in cells with and lacking MLL fusion proteins. Notably, in 
cells transformed by MLL fusion proteins, increased amounts of EAP are 
localized to the Hox loci and the complex is more broadly distributed. 
Furthermore, while EAP recruited independently of MLL fusion proteins 
dissociates from target loci in response to differentiation cues, MLL fusion 
protein-associated EAP remains at target genes, maintaining Hox and Meis 
expression. These findings suggest that a key activity of MLL fusion proteins is to 
prevent the normal dissociation of elongation machinery from loci critical for 
leukemogenesis. 
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Materials and Methods 
Cloning and Transduction of AF9C-term into M1 cells Bases 1691-1963 
encoding residues 478-568 of human AF9 (Accession NP_004520) were PCR-
amplified from an MLL-AF9 expression vector and cloned into the Xho1 and Not1 
sites of a modified murine stem cell virus (MSCV) vector. This vector contains 
two N-terminal FLAG tags, three nuclear translocation signals, and two C-
terminal MYC tags and expresses GFP off of an internal ribosome entry site 
(MIGR1-2XFLAG-3XNLS-2XMYC). MIGR1-2XFLAG-AF9-3XNLS-2XMYC and 
the control MIGR1-2XFLAG-3XNLS-2XMYC were packaged into viruses using 
the 293-derived Plat-E cell line [83]. One ml of viral supernatant and 5 g/ml 
polybrene was added to three million M1 cells (from ATCC) in a six-well tissue 
culture dish. Cells were spin-infected for 90 minutes at 2500 RPM in an 
Eppendorf 5810 R centrifuge. The next day the media was changed. Cells were 
GFP sorted at the University of Michigan Flow Cytometry Core one week after 
transduction. 
Cell lines  M1 (ATCC), M1-control, M1-AF9C-term, RS4;11 (ATCC), KOPN-8 
(DSMZ), REH (ATCC), Raji (ATCC), 697 (DSMZ), NALM-1 (DSMZ), HAL-01 
(DSMZ), and NALM-6 (DSMZ) cells were maintained in RPMI media containing 
10% fetal bovine serum. MV4:11 (ATCC) cells were maintained in IMDM with 
15% FBS and 10 ng/mL IL-3. 293 cells (ATCC) were grown in Dulbecco’s 
Modified Eagle’s Medium (DMEM) supplemented with 10% fetal bovine serum 
(Gibco). E2A-HLF, MLL-AF9, and MLL-ENL transformed bone marrow cells were 
established in our lab. In brief, 6-8 week old C57/BL6 mice were injected with 
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150 mg/kg 5-fluorouracil. Bone marrow was harvested after four days and placed 
in a pre-stimulation IMDM media containing 100 ng/ml SCF, 10 ng/ml IL-3, and 
10 ng/ml IL-6. The next day, cells were transduced with pMSCV-E2A-HLF (a 
generous gift from Dr. Michael Cleary), pMSCV-MLL-AF9, or pMSCV-MLL-ENL 
that was packaged into retroviruses using Plat-E cells as described above for the 
MIGR1 constructs. Forty-eight hours post-transduction, cells were placed in 
selection media containing 1 mg/ml G418 (Invitrogen). Fusion protein-
transformed cells were maintained in IMDM media containing 15% FBS and 10 
ng/ml IL-3. 
LC-tandem MS Protein Identification of EAP by LC-tandem MS Samples 
were resolved by SDS-PAGE and visualized with MS-compatible silver stain 
(PROTSIL-2, Sigma). Whole lanes corresponding to control and AF9 IP were cut 
into 16 slices each and destained following the manufacturer’s protocol. 
Cysteines were reduced with 150 ml of 10 mM DTT followed by alkylation with 50 
mM iodoacetamide (in 0.1M ammonium bicarbonate, pH 8.0) at RT for 30 min 
each. Gel slices were crushed, dried using a vacufuge, and re-swollen in 30 l of 
ammonium bicarbonate buffer containing 500 ng of sequencing grade, modified 
trypsin (Promega). After 5 minutes incubation on ice, another 40 l of ammonium 
bicarbonate buffer was added and digestion was carried out at 37 C overnight.  
An additional 250 ng of trypsin was added 2 hours prior to the extraction of 
peptides.  Peptides were extracted once each with 150 l of 60% acetonitrile 
containing 0.1% TFA and acetonitrile containing 0.1% TFA.  All extracts were 
pooled and concentrated using a vacufuge to a final volume of 30 l. 
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 Ten l of the digest was separated on a reverse phase column (Aquasil 
C18, 15 mm tip x 75 mm i.d. x 15 cm, Picofrit column, New Objectives, Woburn 
MS) using acetonitrile/1% acetic acid gradient system (5-75% acetonitrile over 40 
minutes followed by 95 % acetonitrile wash for 5 minutes) at a flow rate of ~300 
nl/min. Eluted peptides were directly introduced into an ion-trap mass 
spectrometer (LTQ-XL, ThermoFisher) equipped with a nano-spray source. The 
mass spectrometer operated in data-dependent MS/MS mode to acquire a full 
MS scan (400-2000 m/z) followed by MS/MS on the top 5 ions from the full MS 
scan (relative collision energy ~35%). Dynamic exclusion was set to collect 2 
MS/MS spectra on each ion and exclude it for an additional 2 minutes. Raw files 
were converted to mzXML format and searched against mouse IPI database (V 
3.31, 67,611 entries) + reverse database using X!Tandem [84] with k-score plug-
in, an open-source search engine developed by the Global Proteome Machine.  
Search parameters included a precursor peptide mass tolerance window of 3 Da 
and fragment mass tolerance of 0.8 Da.  Oxidation of methionine (+16 Da) and 
carbamidomethylation of cysteines (+57 Da) were considered as variable 
modifications. Search was restricted to tryptic peptides with one missed 
cleavage. X!Tandem outputs were subjected to PeptideProphet [85] and 
ProteinProphet [85] analysis using default parameters of each program.  All 
proteins with a ProteinProphet probability of >0.9 (error rate <3%) were 
considered for further analysis.  MS/MS spectra corresponding to proteins that 
were unique to the experimental sample were manually verified. 
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Immunoprecipitation and Western blots Nuclei were isolated from 200 ml to 
1000 ml of M1 suspension culture by douncing cells in hypotonic buffer (10 mM 
KCl, 10 mM Tris-Cl, pH 7.9) and spinning at 4000 rpm for 15 minutes, 4 C. 
Nuclei were then lysed in BC-300 lysis buffer: 0.1% NP40, 10% glycerol, 300-500 
mM KCl, 100 uM PMSF, 1 protease inhibitor cocktail tablet (Roche), 1 mM 
EDTA, 50 mM Tris-CL pH 7.9 for 30 minutes at 4ºC. Some immunoprecipitations 
were done in the presence of 100 g/ml ethidium bromide or after treatment with 
2500 units of Benzonase (EMD Biosciences) in the presence of 2 mM MgCl2. 
Cell lysate was spun at maximum speed in an Eppendorf 5424 microcentrifuge 
for 15 minutes and supernatant was pre-cleared with protein-G-agarose (Roche) 
beads for 1 hour at 4ºC. After pre-clearing, the lysate was incubated with 100 l 
anti-FLAG M2 agarose beads (Sigma) for 1 hour rocking at 4ºC.  Beads were 
subjected to six five-minute washes with lysis buffer (excluding protease 
inhibitors). For mass spectrometry analysis, the purified proteins were eluted with 
2X FLAG peptide (Sigma, Sequence: DYKDDDDDYKDDDDK) two times for 
fifteen minutes each at 4ºC, resolved by SDS-PAGE, visualized with 
ProteoSilver2 kit (Sigma) according to the manufacturer’s instructions, and 
submitted to the University of Michigan Mass Spectrometry Core. For Western 
blotting, the beads were heated at 90ºC Celsius for 5 minutes in SDS Tris-
Glycine sample buffer (Invitrogen). The supernatant was loaded onto 4-20% Tris-
Glycine gels (Invitrogen), and proteins were transferred to a nitrocellulose 
membrane for 1 hour. Membranes were blocked in 5% non-fat dry milk (Bio-Rad) 
and then incubated with the appropriate primary antibody overnight. Goat anti-
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rabbit or goat anti-mouse secondary antibodies (Santa Cruz) were used at 
1:2000 for 30 minutes. Proteins were detected using SuperSignal West Pico 
Chemiluminescent Substrate (Pierce). Whole cell lysate was used for IPs in 
human leukemia cell lines and antibodies conjugated to Protein G Dynabeads (in 
PBS with 5% BSA) (Invitrogen), prepared by overnight incubation, were used for 
overnight IP (antibodies listed below).  
Gradient Centrifugation FLAG-AF9C-term from M1 cells was immuno-purified as 
described above. The 2X FLAG peptide eluate was loaded onto a 15-45% 
glycerol or 5-20% sucrose gradient and ultracentrifuged at 23,000 rpm, 4 C for 
16 hours in the TH-660 rotor of a Sorvall WX Ultra 80 centrifuge. Protein 
standard, supplemented with Dextran blue (Sigma) for a 2 megadalton marker, 
was run in parallel (GE Healthcare). 200 uL fractions were collected and proteins 
were either concentrated at 14,000 RPM for 2 hours (Millipore, YM-3) for 
Western blot analsysis of sucrose gradient or precipitated with tricholoracetic 
acid (TCA) for mass spectrometry-based analysis. For TCA precipitation, 
samples were first incubated with 2% sodium deoxycholate for 30 minutes on ice, 
then with10% TCA for 1 hour on ice. Samples were spun for 10 minute at 14,000 
rpm, 4 C in an Eppendorf 5424 microcentrifuge, washed with 1 mL cold acetone 
for 10 minutes, and spun again at 14,000 rpm, 4 C for 10 min. After air-drying, 
samples were dissolved in urea buffer (9 M urea, 20  mM HEPES, pH 7.5) for 
mass spectrometric analysis. 
Transient Transfections 105 human embryonic kidney 293 cells were seeded in 
10 cm or 15 cm (for mass spectrometry) dishes overnight. Cells were transfected 
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with 10 µg empty vector, 10 µg pMYC-MLL1116-1397-AF9, 5 µg empty vector and 5 
µg pcDNA-HA-Dot1l, 5 µg pcDNA-HA-Dot1l and 5 µg pFLAG-HA-MLL1116-1397, or 
5 µg pcDNA-HA-Dot1l and 5 µg pFLAG-MLL-AF9, harvested after 48 hours for 
whole cell lysis in BC-300 buffer, and immunoprecipitated overnight with anti-
FLAG M2 (Sigma) or anti-MYC (Clontech) affinity resin. After five five-minute 
washes with lysis buffer, beads were boiled in SDS Tris-Glycine loading buffer, 
loaded onto 6% or 4-20% Tris-Glycine gels, and transferred to nitrocellulose 
membranes. After 1 hour blocking in 5% non-fat milk, blots were incubated with 
anti-HA (Covance), anti-FLAG (Sigma), or anti-CDK9 (Santa Cruz) overnight, 
with secondary antibody for 30 minutes, and subjected to enhanced 
chemiluminescence with SuperSignal West Pico Chemiluminescent Substrate. A 
gel with empty vector and pMYC-MLL1116-1397-AF9 IP’ed samples was silver 
stained with Sigma’s ProteoSilver2 kit and submitted to the University of 
Michigan Mass Spectrometry Core for analysis. 
Chromatin Immunoprecipitation Chromatin immunoprecipitation (ChIP) was 
performed according to Upstate’s protocol using recommended lysis, dilution, 
and wash buffers. In brief, cells were fixed in 1% formaldehyde for 15 minutes at 
room temperature. Cells were pelleted, PBS-rinsed, and snap frozen. After 
thawing, cells were lysed and sonicated at high intensity 30 second on-off cycles 
for 15 minutes in the Diagenode Bioruptor XL. These conditions generated an 
average DNA fragment size of 500 bp as determined by DNA electrophoresis. 
Protein-DNA complexes were collected using antibody-conjugated Protein G 
Dynabeads that were prepared as described above for standard 
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immunoprecipitations (antibodies listed below). After washing the beads, DNA 
was eluted by incubation with SDS buffer (1% SDS, 100 mM sodium 
bicarbonate) for 30 minutes at 42ºC. DNA-protein cross-links were reversed 
overnight in 0.2 M NaCl at 65 C. DNA was purified using the QIAquick PCR 
Purification Kit (Qiagen) and subjected to qPCR as described below. Primer and 
probe sequences are provided in Table 2.1. For the human MonoMac6 leukemia 
cell line, DNA samples were run on an agarose (Invitrogen) gel, amplified by 
standard PCR on an Eppendorf Mastercycler, and visualized with ethidium 
bromide. Primers are listed in Table 2.1.  
Knockdown of DOT1L Knockdown experiments were performed by Stephanie 
Jo of Jay Hess’s lab. MV4:11 cells at a concentration of 10 million cells/ml  were 
transfected with a 500 nM mixture of 2 siRNA oligonucleotides targeting DOT1L 
(Dharmacon) by electroporation using a Bio-Rad GenePulser MXcell. RNA was 
extracted and reverse-transcribed (described below) for qPCR 48 hours post-
transfection. Gene expression was normalized to 5S ribosomal RNA.  
Flavopiridol Experiments MLL-AF9, MLL-ENL, or E2A-HLF cells were seeded 
at 105 cells/ml in growth media. The following day, cells were treated with 0 nM-
200 nM flavopiridol, which was generously provided by Sanofi-Aventis and the 
National Cancer Institute, NIH. Gene expression was analyzed after 24 hours 
of treatment as described below. Viability was assessed by cell counting with 
Trypan blue exclusion at 48 hours. Viability curves were generated using Prism 
5.0 software. 
 Screening of human ALL cell lines was performed by Daniel Sanders of 
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Jay Hess’s lab with assistance from the University of Michigan Center for 
Chemical Genomics (CCG). Cells were seeded at a density of 1250 cells/well in 
a 384-well plate overnight in RPMI-1640 medium containing 10% FBS. 200 nl of 
flavopiridol (stock concentrations of 0.04mM – 5mM) was added using a 
Beckman Biomek FX with a HDR (Beckman Coulter, Fullerton,CA) to give a final 
concentrations of 0.2 -25µM. 10 µM of staurosporine (BIOMOL) was used as a 
positive control for complete cell death and DMSO was used as a negative 
control. The plates were incubated in a 37° C, 5% CO2 incubator for 48 hours. 
Viability was assessed using CellTiter-Glo Luminescent Cell Viability Assay 
(Promega). 25µl of CellTiter-Glo reagent was added to each well using a 
Multidrop (Thermo Scientific) and luminescence was read (gain 3600, 0.76 
sec/well read) with a PHERAstar plate reader (BMG Labtech). pIC50 curves were 
generated using gretl software. 
Treatment with Differentiation Agents MLL-AF9, MLL-ENL, or E2A-HLF cells 
were seeded at 105 cells/ml in growth media. The next day, cells were treated 
with 100 ng/ml IL6 (R&D Systems), 10 nM PMA (Sigma) 5 g/ml LPS (Sigma), 
10 ng/mL G-CSF (R&D Systems) or an equal volume of PBS, ethanol (for PMA), 
or DMSO as a control. 24-72 hours after treatment, cells were counted using 
Trypan blue exclusion or RNA was isolated for gene expression analysis. 
Il-6/LPS-induced Differentiation of Myeloblastic Cells M1-AF9C-term, MLL-AF9, 
MLL-ENL, or E2A-HLF cells were seeded at 105 cells/ml in growth media. The 
next day, cells were treated with 100 ng/ml IL6, 5 g/ml LPS, or an equal volume 
of PBS as a control. At different time points following treatment, cells were 
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collected for morphologic staining with the HEMA-3 stain kit (Fisher Scientific). 
Additional aliquots were prepared for gene expression analysis for Hoxa9, Meis1, 
Gapdh, and beta-actin (described below), standard immunoprecipitation and 
Western blot (described above), or chromatin immunoprecipitation (described 
above). 
Luciferase Reporter Assay 293 cells were seeded in 12 well plates in triplicate. 
The next day the growth media was replaced with OptiMEM (Gibco) media 
supplemented with 0.5% FBS and cells were co-transfected with MIGR1 or 
pMLL-AF9,100 ng Hoxa9-Luc, 15 ng CMV-Renilla and combinations of pCMV-
NPM (from Dr. Sheng-Hao Chao), pCMV-HEXIM (from Dr. Sheng-Hao Chao), 
and pCMV-NPMC+ (from Dr. Sheng-Hao Chao) using Fugene 6 (Roche). Total 
amount of DNA transfected per well was 0.5 g. 48 hours post-transfection cells 
were lysed and assayed for luminescence using Promega’s Dual Luciferase 
Reporter Kit according to the manufacturer’s instructions. Luminescence was 
monitored using a Monolight 3010 luminometer (BD Biosciences). 
Methyl Cellulose Assays Virus was prepared and transduced into murine bone 
marrow as described above, except using MSCV-HA-NPM, MSCV-HA-NPMC+, 
MSCV-FLAG-MLLAF9-IRES-GFP, MSCV-FLT3-ITD. Bone marrow cells were 
plated in Methyl Cellulose (Stem Cell Technologies) with 100 ng/ml SCF (R&D 
Systems), 10 ng/ml IL-3 (R&D Systems), 10 ng/mL GM-CSF (R&D Systems), 10 
ng/ml IL-6 (R&D Systems), and 1 mg/mL neomycin (Gibco) 3 days after 
transduction. Colonies were counted and replated weekly for three weeks. Cells 
were also collected for RNA and morphology analysis at these time points. 
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qPCR  qPCR for ChIPed samples was performed with Taqman primers and 
Taqman Universial Master Mix (Applied Biosystems) using the Applied 
Biosystems 7500 Real-Time PCR system. Primers are listed in Table 2.1. Data is 
expressed as percent of total input using the formula  % Total Input = 2^-[Ct (IP)-
Ct (Input)] [71]. 
For expression analysis, RNA was extracted from cell lines with Trizol 
reagent (Invitrogen) according to the manufacturer’s protocol. Reverse-
transcription was performed using Superscript II (Invitrogen) according to the 
manufacturer’s protocol. FAM-labeled Hoxa9, Meis1, Af9, Enl, Cyclin T2, Dot1L, 
c-Jun, Hexim1, Hexim2, Npm1, Gapdh, -Actin, and U2 snRNA Taqman primers 
(Applied Biosystems) Primer/Probe set number 9 and 11 in Table 2.1 ( for 
detecting abortive and full-length Hoxa9 transcripts) were used in expression 
analysis of murine cell lines. The qPCR reactions were carried out with Taqman 
Universal Master Mix (Applied Biosystems) using Applied Biosystems 7500 Real-
Time PCR system. SYBR Primers detecting FLAG-tagged MLL constructs have 
been previously reported and were obtained from Dr. Andrew Muntean [55]. 
Sequences are provided in Table 3.1. Gene expression was normalized to 
Gapdh for all experiments except the flavopiridol, HMBA, and DOT1L knockdown 
experiments. In the flavopiridol and HMBA experiments, gene expression was 
normalized to U2 snRNA, which is transcribed independently of pTEFb CTD 
kinase activity [86]. For DOT1L knockdown experiments, primers for qPCR were 
designed with MacVector sequence analysis program. Single product formation 
was confirmed by running PCR products on a 1% agarose gel. SYBR Universal 
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Master Mix (Applied Biosystems) was used for qPCR. Data were normalized to 
5S ribosomal RNA. Primer sequences are provided in Table 3.1. Analysis was 
performed using the comparative Ct method [70]. 












Table 3.1 SYBR green primer sequences for gene expression analysis 
Flow Cytometric Analysis E2A-HLF, MLL-AF9, and MLL-ENL cells were 
treated with LPS or PBS as described above. After 24 hours, cells were 
harvested, washed with PBS, and stained for 30 minutes with anti-c-KIT (BD 
Pharmingen) and anti-Gr-1 (BD Pharmingen) conjugated to FITC and PE, 
respectively. Cells were washed with PBS two times, filtered into flow cytometry 
polystyrene tubes with strainer caps, and flow cytometry was performed at the 
University of Michigan Flow Cytometry Core. Data was analyzed using FlowJo 
software.  
CTD Kinase Assay  400 milliion M1-control or M1- AF9C-term cells were lysed in 
the same conditions described above. Anti-FLAG beads (Sigma) were added to 
whole cell lysate for overnight IP as described above. After washes, 100 ng of 
recombinant PolII-CTD (Calbiochem), 100 M ATP, 5 mM MgCl2, and 1 mM 
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DTT, were added to the beads. Reaction mixture was incubated for 1 hour at 
room temperature with rocking. Supernatant was removed, the reaction was 
stopped by addition of SDS loading buffer, and samples were loaded onto a gel 
for SDS-PAGE and Western blotting as described above. 
Antibodies ChIP antibodies include Dot1L (Bethyl, A300-953A, A300-954A 
mixture), ENL (from Dr. Robert Slany), Ring1b (MBL, D139-3), PC3 (Santa Cruz, 
sc-23591) AF4 (from Dr. John Kersey), AF5q31 (from Dr. Robert Roeder), Laf4 
(Abcam, ab-38318), monomeH3K79 (Abcam, ab-2886), dimeH3K79 (Abcam, ab-
3594), trimeH3K79 (Abcam, ab-2621), trimeH3K9 (Abcam, ab-8898), 
trimeH3K27 (Millipore, 07-449), RNA polymerase II (Covance, MMS-126R), 
pSer2-CTD (Covance, MMS-129R), pSer5-CTD (Covance, MMS-134R), Cyclin 
T2 (Santa Cruz, sc-12421), MLL-C (from Dr. Yali Dou), trimeH3K4 (Millipore, 04-
745), NPM1 (Abcam, ab-10530), HEXIM1 (Santa Cruz, sc-48871), HEXIM2 
(Santa Cruz, sc48874), CDK1 (Abcam, ab-18), mouse and rabbit IgG (Santa 
Cruz, sc-2025, sc-2027), IgM (Abcam, ab-9175). Standard IP and Western blot 
antibodies: Cdk9 (Santa Cruz, sc-8338), Cyclin T1 (Santa Cruz, sc-10750), AF4 
(from Dr. John Kersey), Laf4 (Abcam, ab-38318), AF5q31 (from Dr. Robert 
Roeder), ENL (from Dr. Robert Slany), AF9 (Bethyl, A300-597A), Ring1b (MBL, 
D139-3), CBX8 (Abcam, ab-70796), HA (Covance, MMS-101P) Dot1L (Bethyl, 
A300-953A, A300-954A mixture), MLL (Bethyl, A300-086A, A300-087A mixture), 
MLL-C (from Dr. Yali Dou) FLAG (Sigma, F-3165), mouse and rabbit IgG (Santa 
Cruz, sc-2025, sc-2027 ), CDK1 (Abcam, ab-18), pSerine (Qiagen, 37430), 
pThreonine (Qiagen, 37420), pSer5-CTD (Covance, MMS-134R). 
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Results 
MLL1116-1397-AF9 associates with histone-associated proteins and the COP9 
signalosome in 293 cells 
 We began our study of MLL fusion partner associations by transiently 
transfecting 293 cells with the transforming domain of AF9 fused to a small 
portion of N-terminal MLL (MLL1116-1397). In this experiment, mass spectrometry-
based analysis identified the histone-associated proteins, SET (TAF-1), TIF-
1beta, and RBBP4 and 7. SET is a nuclear oncogene that is important in the 
activation of genes through its role as a histone chaperone [87]. SET also 
interacts with CBP and enhances its HAT activity [87,88]. Notably, SET is found 
in translocations with the nucleoporin, NUP214, in pediatric cases of acute T-cell 
lymphocytic leukemias that are characterized by HOXA overexpression [89]. 
SET-associated proteins, TIF-1beta (KAP-1), which is mainly characterized as a 
repressor but serves as a transcriptional activator in embryonic stem cells [90] 
and Protein Phosphatase 2 were also identified in this experiment (Table 3.2). 
Finally, two components of the nucleosome remodeling and deacetylase (NuRD) 
complex [91], RBBP4 (small subunit of CAF-1/RBAP48, p48) and 7 
(RBAP46/p46), were identified in association with MLL1116-1397-AF9. These 
RBBPs were originally identified by their interactions with the Rb tumor 
suppressor, and have since been found to have roles in binding histones and 
stimulating HAT1 activity [92]. The finding that MLL1116-1397-AF9 associates with 
the aforementioned proteins, which have roles in transcriptional activation and 
repression [91,93,94], suggests a couple of possibilities. One is that in the 
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presence of MLL fusion proteins, SET, TIF-1beta, and NuRD components serve 
as transcriptional activators. The other possibility is in line with the ability of MLL 
fusion proteins to repress transcription [16,23,24,25,26], where MLL-AF9 may 
coordinate with transcriptional repressors to suppress the expression of tumor 
suppressors. 
Many subunits of the COP9 signalosome were identified as well (Table 
3.2). Certain COP9 subunits have roles in binding histones and acting as 
transcriptional coactivators at target genes [95], but the COP9 signalosome is 
widely recognized for its role in mediating proteasomal degradation. Given that 
we identified nearly all of the subunits including the ubiquitin-conjugating enzyme 
UBC3B suggests that their function in this MLL1116-1397-AF9-associated complex 
is to degrade substrates, likely MYC- MLL1116-1397-AF9, which is massively over-












Protein Total Peptides Unique Peptides Protein Probability 
MLL 190 17 1 
AF9 20 2 1 
TIF-1beta 6 4 1 
SET 7 4 1 
Rbbp4/7 5 2 1 
Myb binding 
protein 1A 
10 7 1 
Protein 
Phosphatase 2c 
46 22 1 
NPM1 9 3 1 
Rad18 3 2 1 
UBC3B 4 2 1 
COP9 subunit 2 5 3 1 
COP9 subunit 3 4 3 1 
COP9 subunit 4 15 10 1 
COP9 subunit 5 8 5 1 
COP9 subunit 6 8 4 1 
COP9 subunit 7a 4 3 1 
COP9 subunit 7b 4 3 1 
COP9 subunit 8 10 5 1 
Table 3.2 Summary of mass spectrometry-based analysis of proteins associating  
with MYC-MLL1116-1397-AF9 in 293 transfectants Summary of mass spectrometry-
based identification of the COP9 signalosome as MYC-MLL1116-1397-AF9-
associating proteins. Protein probability, total number of peptides, and number of 













The transforming domain of AF9 (AF9C-term) associates with other MLL 
fusion partners and key transcriptional regulators in hematopoietic cells  
Using another approach, we stably-transduced the C-terminal 90 amino 
acids of AF9 into leukemic M1 cells. To ensure efficient nuclear targeting and 
protein purification, we included two N-terminal FLAG-epitope tags, three nuclear 
translocations signals, and two C-terminal MYC tags in this AF9 construct (Fig. 
3.1). Cell extracts were immunopurified with FLAG affinity resin and resolved by 
polyacrylamide gel electrophoresis (PAGE) followed by silver staining (Fig. 3.2A). 
A protein expressing only the tags and nuclear translocation signals 
served as a negative control. Proteins specifically interacting with AF9C-term 
identified by mass spectrometry include MLL fusion partners Af4, Laf4, Af5q31, 
Af10, Ell, and Enl, in addition to Cdk9, Cyclin T1/T2 (pTEFb), Dot1l, Pc3 and 
Ring1b (Fig. 3.2B). A more detailed list, with the number of peptides identified for 
each protein is summarized in Table 3.3. None of the proteins identified in 293 
cells were identified with significance in these experiments. This may be because 
those proteins associate exclusively with MLL1116-1397, they require the tertiary 
structure formed by MLL1116-1397-AF9, they are cell type-specific associations, or 
because they were an artifact of over-expression. We proceeded to characterize 
the proteins that associate with AF9C-term as they are largely characterized as 
transcriptional activators [96,97,98] and thus have important implications in Hox 
regulation and deregulation by MLL fusion proteins. This group of proteins has 




        




Figure 3.2 Mass spectrometry-based identification of AF9C-term-associating 
proteins A) Schematic of experimental design. B) Representative silver-stained 
gel with a list of proteins associating with AF9C-term identified by mass 
spectrometry to the right. Proteins immunoprecipitating with the control fragment 
were subtracted in the analysis in order to identify proteins differentially 
associating with AF9C-term.
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Table 3.3 List of AF9C-term-associating proteins identified by mass spectrometry 
Protein probability, total number of peptides, number of unique peptides, and 
number of experiments in which the proteins were identified are indicated.  
 
 
Associations with Af5q31, Laf4, Cdk9, and Pc3 were verified by Western 







Number  of 
Experiments 
BCoR 23 15 1 5 
Dot1L 9 6 1 6 
Af4 51 24 1 7 
Laf4 126 39 1 11 
Af5q31 213 53 1 10 
Af10 15 9 1 6 
CyclinT1 46 17 1 8 
Cyclin 
T2 
5 2 1 4 
Enl 14 6 1 1 
Ell 37 19 1 5 
Med4 5 3 1 2 
Med6 2 1 1 1 
Med8 3 2 1 1 
Med9 2 2 1 1 
Med18 4 3 1 1 
Med19 2 1 .96 1 
Crsp2 9 6 1 1 
Crsp6 8 5 1 1 
Crsp7 9 5 1 1 
Crsp8 16 8 1 1 
Thrap4 13 9 1 2 
Thrap5 12 6 1 2 
Crsp9 1 1 .93 1 
NPM 2 1 .85 3 
HEXIM1 28 8 1 4 
HEXIM2 21 7 1 5 
MePCE 59 8 1 5 
Larp7 59 8 1 5 
Cdk9 14 6 1 9 
Cdk1 2 2 1 1 
PRMT5 9 3 1 5 
Pc3 1 1 .93 1 
Ring1b 5 3 1 3 
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identified by mass spectrometric-based analysis after the immunoprecipitations 
were carried out in 500 mM KCl and 100 µg/mL ethidium bromide, suggesting 
that they are strong and are not mediated through DNA interactions. Benzonase 
treatment was tested on Dot1l, AF5q31, and Cdk9 associations to confirm the 
ethidium bromide results (Fig. 3.3B). Mass spectrometric analysis identified 
Ring1b and Pc3 after AF9C-term immunoprecipitation in up to 500 mM KCl, but not 
when ethidium bromide was present. Enl, Ell, and Af4 were identified by mass 
spectrometry after immunoprecipitation in 300 mM salt, and whether these 
interactions are DNA-dependent was not tested. 
 
Figure 3.3 Western blot verification of protein associations A) Western blots after 
FLAG IP from M1-Control and M1-AF9C-term cell lines. Antibodies used for 
detection are indicated below blots. B) Detection of associations after nuclease 
treatment. Antibodies used for detection are indicated to the left of the blots. On 
the right, is an ethidium bromide stained agarose gel of DNA present at the 
beginning of the immunoprecipitation in the presence or absence of Benzonase. 
 
To test whether the associations are preserved in the context of the MLL 
fusion protein, we performed immunoprecipitations in 293 transfectants and 
human leukemia cell lines (Fig. 3.4A, C). These experiments showed that like 
MLL-ENL and MLL-AF4 [99,100], MLL-AF9 retains the ability to associate with 
key EAP subunits, including pTEFb, DOTL, and RING1b. Furthermore, chromatin 
immunoprecipitation of different EAP components shows that many of them 
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localize to the HOXA9 locus in MonoMac6 cells, which express the MLL-AF9 
fusion protein (Fig. 3.4B). 
 
Figure 3.4 MLL fusion proteins associate with EAP A) Transient co-transfections 
of 293 cells with an N-terminal fragment of MLL (FLAG-HA-MLL1116-1397) or 
FLAG-MLL-AF9 with HA-Dot1L. B) ChIP for different EAP components (indicated 
above the gels) in MonoMac6 cells at two promoter sites of HOXA9 detected by 
conventional PCR. C) Immunoprecipitation of EAP components from the RS4:11 
and KOPN8 human leukemia cell lines that express the MLL-AF4 and MLL-ENL 
fusion proteins, respectively. Antibodies used in immunoprecipitations are 
indicated above the blots. Proteins were detected using antibodies indicated 
below the blots in the RS4:11 cells and to the right of the blots in the KOPN8 
cells. 
 
In order to address the heterogeneity of EAP, we performed a preliminary 
gradient centrifugation experiment where 2X FLAG eluate after FLAG-AF9C-term-
immunoprecipitation from M1-AF9C-term cells was loaded onto a glycerol gradient 
and ultracentrifuged to separate AF9C-term-containing complexes based on 
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differences in size. Fractions were collected, and proteins were TCA precipitated 
and dissolved in a minimal volume for mass spectrometric-based identification of 
proteins. Detection of the 90 amino acid AF9 fragment was limited by mass 
spectrometry since this technique was only able to identify one peptide of this 
small construct. Stably over-expressed AF9C-term was only detected in the low 
density fractions, suggesting that most of the AF9C-term may be extraneous (Table 
3.4). Western blot analysis on other gradient centrifugation experiments shows 
that AF9C-term is found throughout the gradient, again, with the highest levels in 
the low-density fractions (Fig. 3.5). Western blot analysis of other EAP subunits 
was limited by a combination of low protein levels and poor antibodies. 
 Results from glycerol gradient centrifugation suggest that the EAP 
complex is heterogeneous with an approximately 2 Megadalton RNA polymerase 
II-associated EAP complex, containing FMR2 members, pTEFb, and pTEFb-
associated factors such as the inhibitory HEXIM proteins, LARP7, and MEPCE 
(Table 3.4).  Chromatin-associated proteins such as Dot1L and the Polycomb 
proteins were difficult to detect in these experiments, with Dot1l and Af10 present 
in low abundance in the high-density fractions. This finding supports the model 
proposed by Yokoyama et al. who describe physically distinct pTEFb and Dot1l-
associated complexes that functionally coordinate to regulate transcription [100]. 
Further, purification of Dot1L from stable 293 transfectants led to the 
identification a 2 Megadalton complex termed DOTCom [101]. DotCom consists 
of a few EAP components, including AF9, ENL, and AF10, along with 




Table 3.4 Mass spectrometry-based analysis of AF9C-term-associated proteins 
after glycerol gradient centrifugation Gradient fractions collected from a 15-45% 
glycerol gradient are indicated above the table, with increasing fraction number 
corresponding to increasing density. Proteins identified are listed on the left, with 




                      
Figure 3.5 Western blot analysis of FLAG-AF9C-term after sucrose gradient 
centrifugation 2X FLAG eluate was loaded onto a 5-20% sucrose gradient, which 
was ultracentrifuged for 16 hours. Fractions were collected, concentrated, and 
subjected to SDS-PAGE followed by Western blot for FLAG-AF9C-term. 
     
MLL fusion proteins increase the amount of pTEFb and Dot1L at target loci 
A key question for understanding mechanisms of transformation by MLL 
fusion proteins is how the amount and distribution of EAP subunits at target loci 
differs between cells transformed by MLL fusion proteins versus those 
transformed by other mechanisms. To address this, we established leukemia cell 
 44 
lines by expression of MLL-ENL, MLL-AF9, or E2A-HLF in murine hematopoietic 
progenitor cells and analyzed EAP component expression levels and binding at 
Hoxa9. E2A-HLF transformed cells are not dependent on Hox expression for 
growth [52]. These cells express Hoxa9 at 5-10-fold lower levels than MLL 
fusion-transformed cell lines and have barely detectable expression of Meis1 
(Fig. 3.6). The cells express comparable levels of the EAP components Enl, 
Cyclin T2, and Dot1L while Af9 expression is significantly lower in the MLL fusion 
transformed cells (Fig 3.6). 
  
Figure 3.6 Gene expression in fusion-transformed cell lines qPCR analysis of 
Hoxa9 (left), Meis1 (middle), and EAP (right) expression in the fusion-
transformed cell lines expressed as the fold difference over E2A-HLF- 
transformed cells. Data are normalized to Gapdh. 
 
Although the fusion proteins expressed in these cell lines have N-terminal 
FLAG epitope tags, ChIP experiments using different FLAG antibodies were 
unsuccessful. Hence, AF9 and ENL antibodies were used to detect fusion protein 
binding at target loci. ChIP-qPCR experiments using these antibodies show a 
pattern of binding similar to that we previously reported for a conditional form of 
MLL-ENL [69] or for MLL-AF4 [102] (Fig. 3.7), with peaks in both the promoter 
and coding region of Hoxa9 that contrast with the distribution of MLL, which is 
concentrated at the promoter in cells lacking MLL rearrangements [69]. This 
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pattern of binding is not found after ChIP-qPCR for endogenous Enl and Af9 in 
cell lines that lack MLL fusion proteins (Fig. 3.15 and Fig. 3.18, top panel). An 
interesting note is that while MLL-AF9 appears to recruit wild-type Enl, wild-type 
Af9 levels are minimal at target loci in cells transformed with MLL-ENL. This is 
possibly due to the lower levels of Af9 expression in the MLL fusion-transformed 
cell lines compared to the E2A-HLF-transformed cells.  
 
Figure 3.7 Localization of ENL/MLL-ENL and AF9/MLL-AF9 to target loci A) 
ChIP-qPCR analysis of binding at Hoxa9 locus. Schematics of Hoxa9 are 
depicted below the graphs, with red arrows indicating transcription start sites and 
black boxes indicating exons. HD is the homeodomain-encoding exon. B) ChIP-
qPCR in the coding region of the Meis1 locus after immunoprecipitation of the 
proteins indicated along the x-axis. 
 
Until recently, pTEFb has mainly been studied in the context of HIV [103]. 
It is a crucial co-factor to the viral protein, Tat, which recruits pTEFb to TAR 
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elements of nascent viral transcripts in order to overcome abortive transcription. 
Tat-mediated transactivation is absolutely dependent on pTEFb activity, and the 
importance of pTEFb in the development of other diseases, such as cardiac 
hypertrophy and cancer, is being established, as well [103].  
pTEFb phosphorylates Serine 2 of the RNA polymerase II (Pol II) CTD as 
well as the 5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) sensitivity 
inducing factor DSIF, thereby releasing RNA pol II from elongation inhibition 
[104]. One possibility is that MLL fusion proteins deregulate Hox expression 
through recruitment of excessive pTEFb to target loci thereby resulting in 
unregulated transcriptional elongation. We tested for evidence of RNA 
polymerase II stalling at the Hoxa9 locus in the fusion-transformed cell lines. We 
used qPCR primers within the first 100 bases of the transcriptional start site of 
Hoxa9 as an indicator of abortive transcription and within the last exon of Hoxa9 
as an indicator of complete transcription. The amount of short transcripts greatly 
exceeds that of mature transcripts in the E2A-HLF transformed cells, with only 
20% of the initiated transcription developing into mature transcripts. There are 
higher levels of full-length transcripts in the MLL fusion transformed cells, with 
full-length transcripts comprising 40 to 80% of all transcripts  (Fig. 3.8). 
In keeping with this, ChIP for the pTEFb component Cyclin T2 showed 
that more Cyclin T2 is localized to the coding regions of Hoxa9 and Meis1 in cells 
with MLL fusion proteins than in those lacking MLL rearrangements (Fig. 3.9A, 
B). In cells transformed by E2A-HLF, ChIP for Pol II showed that it is present at 
Hoxa9 and Meis1 similar to levels in MLL-AF9-transformed cells (Fig. 3.9A, B). 
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Serine 5 CTD phosphorylation, a modification associated with Pol II 
transcriptional initiation, is also present at levels similar to MLL-AF9-transformed 
cells at Hoxa9. However, cells expressing MLL fusion proteins show 2 to 10-fold 
more Serine 2 phosphorylated Pol II at the Hoxa9 and Meis1 loci (Fig. 3.9A, B). 
These data indicate that, while Hoxa9 transcription in the E2A-HLF cells is 
initiated at levels similar to MLL-AF9-transformed cells, it is lacking in its ability to 
progress to transcriptional elongation. However, the MLL fusion transformed cells 
are able to overcome this elongation block at the Hoxa9 promoter, likely due to 
pTEFb recruitment.  
 
                                
Figure 3.8 RNA polymerase II stalling at Hoxa9 qPCR for mature (3’) and 
abortive (5’) Hoxa9 transcripts in fusion-transformed cell lines with PCR primers 
that amplified the HD-encoding exon or 100 bp downstream from the 
transcriptional start site. Data are expressed as the amount of mature transcripts 
over total initiated transcripts and are normalized to Gapdh.  
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Figure 3.9 Association of MLL fusion proteins with elongating RNA polymerase II 
ChIP-qPCR experiments for different RNA polymerase II associated factors at 
Hoxa9 (A) and Meis1 (B). Schematics of Hoxa9 are depicted below the graphs, 
with red arrows indicating transcription start sites and black boxes indicating 
exons. HD is the homeodomain-encoding exon. p values are provided for the 
differences in binding between the MLL-AF9 and E2A-HLF-transformed cells at 





Assessment of pTEFb as a therapeutic target 
Other groups have also reported the importance of transcriptional 
elongation to MLL fusion protein-mediated transcription. It was shown that knock-
down of ENL compromises transcriptional elongation, and that ENL, AF4, and 
AF5q31 stimulate elongation in an RNA tethering assay. Furthermore, loss of the 
pTEFb interaction domain in AF4 family members, abrogates the fusion protein’s 
leukemogenicity [99,100,105]. These data altogether suggest that the kinase 
activity of pTEFb is a potential therapeutic target in leukemias with MLL 
rearrangements. To assess whether cells transformed by MLL fusion proteins are 
differentially sensitive to CDK9 inhibition, we treated murine AML cell lines 
transformed by E2A-HLF, MLL-AF9, and MLL-ENL as well as a range of human 
ALL cell lines harboring different chromosomal translocations (RS4;11, KOPN-8, 
REH, 697, NALM-1, HAL-01, NALM6, RAJI) with the cyclin-dependent kinase 
inhibitor, flavopiridol, which has a Ki of 3 nM with CDK9 and weaker inhibition of 
other CDKs [106], and measured effects on cell viability and gene expression. 
Viability assays showed that cell lines with MLL fusion proteins are modestly 







   
Figure 3.10 Sensitivity of leukemic cell lines to flavopiridol A) Viability assay in 
murine fusion-transformed cell lines. B) Viability assay (contributed by Daniel 
Sanders) in human leukemia cell lines carrying various chromosomal 
aberrations. 
 
Flavopiridol treatment results in decreased Hoxa9 and Meis1 expression, but 
other constitutively expressed genes such as Gapdh and beta-actin are also 
affected in the MLL-ENL-transformed cells (Fig. 3.11), a finding that is consistent 
with the general role of pTEFb in transcriptional regulation [107,108]. Thus, the 
MLL fusion transformed-cell lines are not more sensitive to flavopiridol due to 
selective inhibition of Hoxa9 transcription. In fact, at higher concentrations, 
flavopiridol more effectively inhibits Hoxa9 expression in low-expressing E2A-
HLF transformed cells, even more so than the house-keeping genes (Fig. 3.11). 
It is also possible that the inhibition of other cyclin-dependent kinases may be 
leading to the toxicity and gene expression decreases observed in these assays. 
Of note, flavopiridol is currently in clinical trials for the treatment of leukemia and 
other cancers, and its potency is attributed to inhibiting many CDKs. 
Nonetheless, in combination with other drugs, it is showing promise as a 
therapeutic as it targets cycling cells and recruits quiescent leukemic cells into a 
proliferative state [109,110,111]. However, it is largely protein-bound and the 
dosage is limited by diarrhea and other side effects. 
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Figure 3.11 Effects of flavopiridol on gene expression qPCR analysis of gene 
expression in MLL-ENL (left) and E2A-HLF (right) transformed cells after 24 hour 
treatment with flavopiridol. Data are normalized to U2 snRNA. 
  
Assessment of Dot1L as a therapeutic target 
Dot1L is different from other histone lysine methyl transferases in that it 
does not have a SET domain, and it methylates H3 in the globular domain of the 
nucleosome [112]. Furthermore, it is the only known H3K79 methyl transferase. 
Characterizing this enzyme in normal and pathological conditions has been an 
active area of research for the past several years. Although Dot1L is necessary 
for mammalian development [113], loss of Dot1L is relatively well-tolerated in 
adult mice (Jo et al, in preparation). This, along with its unique catalytic activity, 
makes it an attractive candidate as a therapeutic target.  
ChIP studies performed for Dot1l show that the enzyme is present at 
elevated levels at MLL fusion target loci in a pattern similar to the MLL fusion 
proteins (Fig. 3.12A, B). While monomethylation of H3K79, a regulatory mark 
[96], is higher in the E2A-HLF cells, di and trimethylation of H3K79, marks 
associated with active transcription [96], are higher in cells transformed by MLL 
fusion proteins, showing a broad distribution across the locus. These findings are 
consistent with recent ChIP experiments performed on human ALL cell lines 
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[102] and primary ALL blasts [50], which show that precursor B ALLs with MLL 
rearrangements show large blocks of histone H3 lysine 79 di-methylation at the 
HOXA9 locus compared to leukemic cells lacking MLL rearrangements. Elevated 
levels of Dot1L and its associated H3K79 di and trimethyl marks are also seen in 
the coding region of the Meis1 locus (Fig. 3.12B). Trimethylated H3K79 is 
consistently higher at Hoxa9 and Meis1 in MLL-AF9 transformed cells compared 
to MLL-ENL transformed cells even though MLL-ENL transformed cells express 
higher levels of these genes. This may be because MLL-AF9, which contains the 
90 C-terminal amino acids of AF9, is capable of recruiting positive regulators of 
Dot1L-mediated trimethylation, while MLL-ENL, which contains most of the ENL 
protein, is not able to perhaps due to the presence of regulatory domains. In 
regards to the association of H3K79 trimethylation with expressed genes, the C-
terminus of AF9 may not be sufficient for optimal transcriptional activity [100]. 
MLL-AF9 transformed cells lag behind MLL-ENL transformed cells in their levels 
of RNA polymerase II-associated factors at target loci (Fig. 3.9), which may be 
why they express lower levels of target genes.  
Knockdown of Dot1L in cells with MLL rearrangements show decreased 
Hoxa9 and Meis1 expression, demonstrating the importance of Dot1L to MLL 
fusion protein-mediated gene activation (Fig. 3.13, contributed by Stephanie Jo) 
[50]. Remarkably, our initial studies with Dot1L conditional knockout mice show 
that transformation by MLL-AF9 is absolutely dependent on Dot1L, while other 
oncoproteins, such as E2A-HLF or the combination of HOXA9 and MEIS1, are 
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not (Stephanie Jo, Hess lab), suggesting that loss of Dot1L function is not 
generally toxic to myeloid cells.  
 
Figure 3.12 Association of MLL fusion proteins with Dot1L ChIP-qPCR performed 
for Dot1L and its associating H3K79 methylation marks at Hoxa9 (A) and Meis1. 
(B). Schematics of Hoxa9 are depicted below the graphs, with red arrows 
indicating transcription start sites and black boxes indicating exons. HD is the 
homeodomain-encoding exon. IgG controls are shown in Figure 3.9. 
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Figure 3.13 Knockdown of Dot1L in MV4:11 Cells qPCR detection of Dot1L, 
Hoxa9, and Meis1 after siRNA-mediated knockdown of DOT1L expression in the 
MV4:11 human leukemia cell line. 
 
EAP association with target loci is dynamic and is altered by recruitment  
via MLL fusion proteins 
Previous studies in 293 cells, as well as the work reported here, indicate 
that the EAP complex regulates Hoxa9 and Meis1 transcription both in cells with 
and lacking MLL rearrangements [105]. Since the composition of the complex 
appears to be similar, the question arises how regulation of the complex is 
altered by MLL fusion proteins so that this does not allow for down-regulation of 
target genes. One attractive possibility is that through fusion with MLL, EAP 
association with target loci becomes dependent not only on interactions mediated 
by EAP subunits, but also on the amino terminal MLL sequences. The presence 
of a number of DNA binding motifs including the AT hooks, DNMT domain, as 
well as interactions with menin, PAFc, or wild-type MLL [55,57,73], could result in 
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tighter association with target loci, making dissociation of the complex resistant to 
normal physiologic differentiation cues.   
To explore this further, we first developed a model system in which we 
could study the association of EAP with target loci during the induction of myeloid 
differentiation. Myeloblastic M1 cells and our stably-transduced M1-AF9C-term cell 
line differentiate into macrophages in response to IL-6 (Fig. 3.14A, [114]), with 
dramatic down-regulation of Hoxa9 and Meis1 evident after 24 and 4 hours of 
treatment, respectively (Fig. 3.14B). An interesting note is that the stably over-
expressed AF9C-term localizes to Hoxa9 and Meis1. To date, Af9 has not been 
shown to directly regulate Hoxa cluster genes [115]. This result may be due to 
over-expression of AF9C-term. Another possibility is that the retroviral integration 
that occurred upstream of Hoxa9 and Meis1 in the M1 cell line [116,117], may 
recruit Af9 as a means to Hoxa9 and Meis1 overexpression. 
 
 
Figure 3.14 IL-6-induced differentiation of M1 cells A) Wright-Giemsa stained 
cells after 48 hours of IL-6 treatment. B) Gene expression of Hoxa9 and Meis1 
after 4, 8, or 24 hours of IL-6 treatment. 
 
The decreases in Hoxa9 and Meis1 expression are accompanied by rapid 
dissociation of EAP subunits including Af9, Cyclin T2, and Dot1 from the Hoxa9 
 56 
locus, which is evident as early as 4 hours (Fig. 3.15B, C). Notably, with the 
exception of endogenous Af9, decreases in EAP expression are not detected 
until 8 hrs post-treatment (Fig. 3.15A), indicating that the dissociation precedes 
EAP down-regulation in differentiating cells. The MYC-AF9 is stably expressed 
by an MSCV promoter, and its expression is presumably independent of IL-6-
mediated gene regulation. Af9 and Enl were the earliest to dissociate from the 
Meis1 locus (Fig. 3.15C), and it remains to be seen whether their dissociation 
precedes Meis1 down-regulation. Thus, there may be differences in regulation 
between Hoxa9 and Meis1 in this experimental model.  
 
Figure 3.15 Expression and localization of EAP subunits during IL-6-induced 
differentiation of M1 cells A) Expression of EAP components after 4 and 8 hours 
of IL-6 treatment. B) ChIP for different EAP subunits indicated above the graphs 
at 4 and 8 hours. Schematics of Hoxa9 are depicted below the graphs, with red 
arrows indicating transcription start sites and black boxes indicating exons. HD is 
the homeodomain-encoding exon. C) ChIP for EAP components in the coding 
region of Meis1. 
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We then utilized the E2A-HLF, MLL-ENL, and MLL-AF9 transformed cell 
lines to test if EAP dissociation is altered by MLL fusion proteins. We screened a 
panel of differentiation agents to assess the sensitivity of the cell lines as 
measured by changes in Hoxa9 expression (Fig. 3.16). These experiments show 
that LPS down-regulates Hoxa9 expression by approximately 60% in E2A-HLF 
transformed cells, but not in MLL fusion transformed cells.      
              
Figure 3.16 Hoxa9 expression after 48 hour treatment with differentiation-
inducing agents qPCR for Hoxa9 expression after treatment with IL-6, GCSF, 
PMA, or LPS. Data are expressed as fold difference over PBS (IL-6, G-CSF, 
LPS) or ethanol (for PMA)-treated cells. Data are normalized to beta-actin. 
 
E2A-HLF transformed murine bone marrow cell lines are highly sensitive 
to induction of differentiation with lipopolysaccharide (LPS) (Fig. 3.17A-C), with 
dramatic downregulation of Hoxa9 (Meis1 is barely detectable in these cells) 
observed after 24 hours of LPS treatment (Fig. 3.17C). In contrast, cells 
transformed by MLL-AF9 or MLL-ENL do not show appreciable Hoxa9 or Meis1 
downregulation or differentiation (Fig. 3.17A-C). To show that LPS signaling is 
intact in the MLL fusion transformed cell lines, we tested the expression of c-Jun, 
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a target gene of LPS signaling [118]. Both MLL transformed cell lines showed 
upregulation of c-Jun, although the increase in MLL-AF9 transformed cells is 
relatively modest (Fig. 3.17C). It remains possible that E2A-HLF transformed 
cells express higher levels of the LPS receptor, co-receptors, or signaling 
intermediates or regulators. However, since the proteins involved in the LPS 
signaling pathway in myeloblasts is unknown, this possibility could not be tested. 
Another explanation for the observed difference in Hox expression is that 
the MLL fusion protein alters association of EAP with target loci. In support of 
this, ChIP shows that in E2A-HLF transformed cells, key EAP subunits, including 
Enl, Af9, and Dot1l, dissociate from the Hoxa9 and Meis1 loci in response to LPS 
(Fig. 3.18A, B). In contrast, cells transformed by either MLL-AF9 or MLL-ENL 
show persistent association of these EAP subunits with the loci after LPS 
treatment. It is possible that a consequence of EAP dissociation is the 
dissociation of RNA polymerase II as we detected decreases in total Pol II 
binding at Hoxa9 and Meis1 in terminally differentiated E2A-HLF cells, while Pol 
II levels at these loci in MLL fusion-transformed cells were unchanged or 
elevated (Fig. 3.18A,B).  
There are other explanations as to how EAP subunits may be retained at 
target loci by MLL fusion proteins. The MLL fusion protein may recruit other 
proteins to target loci in order to maintain EAP association, or they may prevent 
the recruitment of proteins that displace EAP from target loci. Insight into these 
possibilities may be gleaned from the identification of proteins associating with 
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EAP after LPS treatment in LPS-sensitive E2A-HLF transformed cells versus 
LPS-resistant MLL fusion transformed cells. 
 
Figure 3.17 MLL fusion transformed cell lines are resistant to LPS-induced 
differentiation A) Wright-Giemsa staining of cells after 24 hour LPS treatment. B) 
Flow cytometric analysis on LPS- and PBS-treated cell lines for forward scatter 
(size), side scatter (granularity), and the cell surface differentiation markers c-Kit 
and Gr-1. Black and blue graphs represent PBS and LPS treated cells, 
respectively. Percentage of total cells in the gated region is indicated in the top-




Figure 3.18 Dissociation of EAP from target loci after LPS treatment A) ChIP-
qPCR for EAP components across Hoxa9 in leukemia cell lines after 24 hours of 
LPS treatment. Schematics of Hoxa9 are depicted below the graphs, with red 
arrows indicating transcription start sites and black boxes indicating exons. HD is 
the homeodomain-encoding exon. B) ChIP-qPCR for binding in the coding region 
of Meis1. Note that each cell line was subjected to experimentation on different 
days. Thus, % Total Inputs may not be directly comparable between the three 










Mechanism of the Fusion Partner 
The mechanism by which MLL translocation partners deregulate 
transcription is beginning to be defined. One of the first insights was provided by 
Bitoun et al. who identified proteins in human embryonic kidney cells that 
associate with the MLL translocation partner AF4, including ENL, AF5q31, CDK9 
and CYCLIN T1 [119]. AF4, in association with ENL and AF9, was found to 
stimulate activity of the RNA polymerase II (RNA Pol II)-CTD kinase pTEFb and 
the histone methyltransferase DOT1L. Subsequently, we reported a complex of 
proteins termed EAP for ENL-associated Proteins or Elongation Assisting 
Proteins that interacts with the MLL translocation partner ENL in 293 cells [105]. 
EAP is similar to the complex reported by Bitoun et al. but includes a number of 
additional interacting proteins such as AF10, PC3, RING1b and others. 
Importantly, the amino acids in ENL that directly interact with DOT1L were found 
to be essential for MLL-ENL to transform bone marrow progenitors. This, 
together with earlier data showing that the MLL-DOT1L fusion is sufficient for 
leukemic transformation [98], suggested that DOT1L methyltransferase activity is 
crucial for HOX gene deregulation and transformation seen in leukemias with 
MLL rearrangements.  
 pTEFb, which interacts with AF4 family members [99,100,120] has also 
been shown to be critical to MLL fusion protein-mediated transformation [100]. 
Yokoyama et al highlight the importance of pTEFb, which is shown to be part of a 
core complex termed AEP that is physically distinct from the DOT1L complex. 
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They show that fusing the pTEFb-interacting domain of AF4 family members to 
MLL is necessary and sufficient for leukemic transformation, while contrary to a 
previous report [98], DOT1L is not sufficient. However, the authors do not rule 
out the importance of DOT1L to transformation. Thus, both CTD kinase and 
histone methyl transferase activities of MLL fusion protein complexes appear to 
be critical to their ability to aberrantly activate the expression of leukemogenic 
genes. 
Significance 
Deregulation of the A cluster HOX genes and MEIS1 is emerging as a 
very common mechanism of transformation in acute leukemia [34]. It is also 
becoming apparent that controlling transcriptional elongation plays a central role 
in regulating transcription at these loci. The Drosophila Hox genes Ultrabithorax 
and Abdominal-B, for example, have Pol II associated with their proximal 
promoters, even though they are not expressed [121]. Similarly, Pol II is also 
present at silenced genes in mammalian cells [122]. Furthermore, mutations in 
elongation factors elongin A or Cdk9 result in homeotic defects associated with 
Pol II stalling [123].   
Just as transcriptional elongation is regulated in the developing embryo, 
deregulation of transcriptional elongation is emerging as an important 
mechanism in growth regulation and oncogenesis. For example, high levels of 
CDK9 expression are associated with a variety of solid tumors including 
neuroblastoma, primitive neuroectodermal tumors, prostate cancer and a wide 
range of lymphomas [124]. The mechanisms regulating CDK9 association with 
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promoters are incompletely defined. In some cases, recruitment appears to 
mediated by the bromodomain containing-protein BRD4, while in other cases, 
specific transcription factors such as MYC recruit pTEFb directly [97]. From work 
presented here and in previous experiments [105,119], it now is clear that 
another recruitment mechanism, particularly important for Hox gene regulation, 
involves interactions with the EAP complex.   
The amount of evidence showing that deregulated recruitment of DOT1L 
plays a role in oncogenesis is also increasing rapidly. One of the first connections 
was that DOT1L interacts with the MLL translocation partner AF10 and that its 
methyltransferase activity is important for MLL fusion protein-mediated 
transformation [98]. Subsequent studies and the work reported here implicate 
DOT1L in transformation by other MLL fusion proteins (MLL-AF4, MLL-ENL, 
MLL-AF9) as well as by the CALM-AF10 translocation in AML and SET-NUP214 
in T-ALL [50,89,105].  As is the case for pTEFb, the mechanisms regulating 
DOT1L association with target loci are poorly understood.   
By association with the EAP complex, both CDK9 and DOT1L would be 
coordinately recruited to target promoters such as the HOX loci.  While many 
mechanisms are possible, one possibility is that EAP is recruited via the YEATs 
domains in AF9 or ENL, which bind histones H1 and H3 [77], wild-type MLL 
[15,73], or AF10’s PHD finger, a domain that binds trimethylated histone 3 in 
other proteins [15,125]. The central role of AF9 and ENL in transcriptional 
regulation of the HOX loci is highlighted by the histone H3 lysine 79 
demethylation and loss of HOX transcription with ENL knockdown [105] and by 
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the finding that Af9 knockout mice show homeotic transformations and posterior 
shifts in Hox gene expression [115]. Importantly, our experiments show that EAP 
association with target loci is dynamic and under active regulation, as the 
complex rapidly dissociates from the Hox and Meis loci within 4 hours of 
treatment with differentiation-inducing agents.  
A number of possible models can be imagined for how the EAP complex 
results in persistent high-level Hox transcription in cells with MLL fusion proteins.  
The finding of increased levels of EAP subunits in the presence of MLL fusion 
proteins and the lack of silencing of the Hox and Meis loci in these cells in 
response to induction of differentiation suggests the model shown in Fig. 3.19. In 
this model, fusion of EAP subunits to N-terminal MLL sequences, as occurs in 
mixed lineage leukemia, alters association of the EAP complex so that levels of 
the complex are increased and dissociation is impaired. This results in persistent 
Hox and Meis gene expression in spite of differentiation signaling cues.  
                               
Figure 3.19 Model for EAP regulation of Hox genes in hematopoietic cells with 
and lacking MLL rearrangements 
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Remaining questions 
Other activities of EAP 
There are other potential activities of the EAP complex that have yet to be 
explored. A robust phospho-Ser5 activity on RNA polymerase II was detected 
after immuno-purification of AF9C-term-associated proteins from M1 cells and 
incubation with recombinant CTD (Fig. 3.20). Interestingly, a higher weight band 
at the expected size of endogenous hyper-phosphorylated RNA polymerase II 
was detected as well. This indicates that AF9 C-term associates with either hyper-
phosphorylated RNA polymerase II or hypo-phosphorylated RNA polymerase II 
that was phosphorylated in the kinase reaction.  
                 
Figure 3.20 phospho-Ser5 CTD kinase activity of EAP A schematic of the 
experimental design is shown on the left. After immunoprecipitation and washing, 
FLAG beads were incubated with recombinant RNA polymerase II CTD in a 
kinase reaction mixture that contains ATP. On the right, is a blot for phospho-
Ser5 after the kinase reaction. The arrows indicate Ser 5 phosphorylated 
recombinant CTD (lower arrow) and hyper-phosphorylated RNA polymerase II 
(upper arrow).  
 
ChIP data show that MLL fusion protein-transformed cells have elevated levels of 
phospho-Ser5 (Fig. 3.9) and in the case of MLL-ENL, RNA polymerase II, and 
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mass spectrometric-based analysis (Table 4) of AF9 C-term -associating proteins 
identified 13 subunits of the Mediator complex (Table 3.3), which is involved in 
assembly of the pre-initiation complex and bridges RNA polymerase II to 
transcription factors. Altogether, these data implicate EAP in early steps of RNA 
polymerase II maturation.  
There are many CDKs that are reported to phosphorylate Ser5 of RNA 
polymerase II, such as CDK7 and CDK1, the latter of which was identified by 
mass spectrometry to associate with AF9 C-term. By Western blot, an association 
with the transforming domain of AF9 was weakly detected (Fig. 3.21A). However, 
ChIP for CDK1 at the Hoxa9 locus of MLL-ENL-transformed cells shows that it is 
present, while there is barely any CDK1 detectable at Hoxa9 in the E2A-HLF-
transformed cells (Fig.  3.21B).  
 
Figure 3.21 Association of CDK1 with EAP A) Western blot for CDK1 after AF9 C-
term purification from M1 cells. B) ChIP-qPCR for CDK1 at Hoxa9 in fusion-
transformed cells. Schematics of Hoxa9 are depicted below the graphs, with red 
arrows indicating transcription start sites and black boxes indicating exons. HD is 
the homeodomain-encoding exon. 
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Thus, CDK1 is associated with the Hoxa9 locus, however a close connection with 
the EAP complex is not convincing. It is worth exploring whether other kinases 
may be responsible for Ser5 phosphorylation of RNA polymerase II seen in the in 
vitro assay. The other possibility is that pTEFb has the ability to phosphorylate 
Ser5 in these experimental conditions.  
Regulation of EAP  
Defining how cell signaling pathways impinge upon EAP’s activity and 
association with DNA is another important topic for future investigation. It is 
noteworthy in this regard that both Lilliputian, the Drosophila homolog of 
AF4/FMR2, and Dot1 appear to be downstream effectors of the RAS signaling 
pathway [126]. Dot1L is also linked to the Wnt signaling pathway, which is 
essential to the development of leukemia cells [101,127]. In our experiments, we 
identified many phospho-sites in several different EAP components. Interestingly, 
a motif that is recurrent in many EAP subunits was phosphorylated in LAF4, 
AF5q31, Cyclin T2, and AF9 (Fig. 3.22).  
                  
Figure 3.22 CDK consensus site in EAP components CDK consensus site is in 
red. Peptides are from EAP components indicated to the right. “p” indicates 
phosphorylated serines identified by mass spectrometry. 
 
This motif, SPXK, is a CDK consensus site [128] and is found in critical domains 
of EAP components, including the transactivation domain of AF9 and the histone 
methyl transferase domain of Dot1L. It is also found among the AT hooks of MLL 
and other DNA binding proteins. Furthermore, a study predicting substrates of 
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CDK1 identifies Dot1L and the MLL homolog ASH1 as potential substrates [129]. 
 In order to explore whether phosphorylation might be an important mode 
of regulation of the EAP complex, we immunoprecipitated AF9 C-term from M1 cells 
after PBS or LPS treatment and blotted with phospho-threonine and phospho-
serine antibodies (Fig. 3.23, left). Interestingly, we found a downward shift in 
migration of a band corresponding to the size of AF9 C-term (Fig. 3.23, left), 
possibly indicating that AF9 C-term is dephoshorylated in response to IL-6 
signaling. However, an anti-FLAG blot for FLAG-AF9 C-term is necessary to ensure 
that these bands are reflecting changes in AF9C-term rather than some other 
protein. 
       
Figure 3.23 Western blot for AF9 C-term -associating proteins after 24 hours of IL-6 
treatment FLAG-Control or FLAG-AF9C-term was IP’ed from IL-6-treated M1-AF9 C-
term cells. Arrows indicate what are proposed to be the hyper- and hypo-
phosphorylated forms of AF9. Antibodies used for detection are indicated below 
the blots. 
 
To determine if this modification altered AF9 C-term’s ability to interact with other 
EAP subunits, we blotted for Cyclin T1 and Cdk9 as well (Fig. 3.23, right). These 
two associations were retained in spite of the modifications to AF9C-term. Thus, it 
could be hypothesized that IL-6 signaling, which induces differentiation through 
the JAK-STAT pathway in M1 cells [130], leads to the dissociation of AF9 C-term 
and pTEFb from DNA (Fig. 3.15), possibly through direct or indirect post-
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translational modifications (PTMs) of AF9C-term. However, these EAP components 
remain associated together. It is possible that they relocate to other genes or are 
sequestered away as an inactive complex. Whether other associations such as 
those with Dot1L and the Polycomb proteins are maintained in response to 
differentiation was not tested. It will be interesting to see to what extent this 
complex remains associated in different physiological conditions.  
 Of further interest is the identification of signaling pathways that maintain 
or enhance EAP associations and enzymatic activity. Firstly, it is important to 
know which phosphorylation or other PTM sites are critical to localization, protein 
and DNA interactions, and enzymatic activities and to identify the enzymes 
responsible for them. This may reveal new therapeutic targets, such as kinases, 
phosphatases, and other enzymes that are aberrantly activated in MLL-
rearranged leukemias. 
EAP association with transcriptional repressors  
Paradoxically, we and other groups identified transcriptional repressors in 
association with AF9 and ENL [78,79,131]. Preliminary experiments show that 
the MLL fusion-transformed cells have higher levels of Pc3 and Ring1b at Hoxa9 
and Meis1 than the E2A-HLF-transformed cells (Fig. 3.24), which have much 
lower levels of expression of these genes (Fig. 3.6). Their binding appears to be 
independent of H3K27 and H3K9 repressive marks, which are similar between 
the two cell lines (Fig. 3.24). Furthermore, Ring1b dissociates along with 
transcriptional activators in response to IL-6-induced Hoxa9 downregulation (Fig. 
3.25). We also assessed binding of Polycomb proteins and associating 
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repressive marks at the Hoxa9 locus after LPS treatment. In E2A-HLF 
transformed cells that experience reductions in Hoxa9 after LPS treatment (Fig. 
3.17C), Ring1b remains at the locus, while Pc3 dissociates (Fig. 3.26A, top 
graphs). There are slight decreases in H3K27 trimethylation and increases in 
H3K9 trimethylation, which are histone marks associated with silenced genes 
(Fig. 3.26A, bottom graphs). In the MLL fusion protein-transformed cells, which 
maintain Hoxa9 expression after LPS treatment, both Pc3 and Ring1b dissociate 
from Hoxa9 (Fig. 3.26B, C, top panels). H3K9 and H3K27 trimethylation levels 
remain unchanged or decrease at Hoxa9 in these cells (Fig. 3.26B, C, bottom 
panels). One explanation is that a proper balance of the Polycomb proteins is 
important to maintaining the structural integrity of the EAP complex. However, it 
is also possible that they have yet to be discovered roles in transcriptional 
regulation. Indeed, ongoing experiments are revealing that Polycomb proteins 
have roles in transcriptional activation during leukemogenesis (Jiaying Tan, Hess 
lab). Other groups have also implicated Ring1b and other Polycomb proteins in 
the activation of Hox genes during embryonic development and propose that they 
may be required for H3K9 acetylation, a mark associated with transcriptionally 
active genes [132,133]. 
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Figure 3.24 Polycomb binding at Hoxa9 ChIP-qPCR for Polycomb proteins and 
associating repressive histone marks. Schematics of Hoxa9 are depicted below 
the graphs, with red arrows indicating transcription start sites and black boxes 
indicating exons. HD is the homeodomain-encoding exon. IgG controls are 
shown in Fig. 3.36 for top panel and Fig. 3.21 for bottom panel. 
 
 
Figure. 3.25 Dissociation of Ring1b from Hoxa9 locus in differentiating M1-AF9 C-
term cells ChIP-qPCR for Ring1b and transcriptional activators at Hoxa9 after 24 
hour IL-6 treatment. Schematics of Hoxa9 are depicted below the graphs, with 
red arrows indicating transcription start sites and black boxes indicating exons. 
HD is the homeodomain-encoding exon. 
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Figure 3.26 Polycomb dissociation from Hoxa9 after 24 hours of LPS treatment 
ChIP-qPCR for Polycomb proteins and associating repressive histone marks. 
Schematics of Hoxa9 are depicted below the graphs, with red arrows indicating 




The pTEFb inhibitors HEXIM1 and HEXIM2 were also found to associate 
with AF9 C-term. The HEXIM proteins, in association with 7SK snRNA, inhibit the 
catalytic activity of CDK9 and are thought to sequester pTEFb away from DNA 
[103]. Our finding that AF9 C-term associates with these inhibitory constituents 
indicates that there is either a separate EAP inhibitory complex sequestered 
away from DNA or that HEXIM is at AF9 C-term target loci. We performed ChIP to 
explore whether HEXIM localizes to DNA with the active EAP complex and 
indeed detected HEXIM1 at Hoxa9, with similar amounts between the E2A-HLF 
and MLL-ENL-transformed cells (Fig. 3.27A). HEXIM1 levels are present at 
significantly higher levels at Meis1 in the E2A-HLF cells (Fig. 3.27B), which have 
barely detectable Meis1 expression.  
We also tested for the presence of the HEXIM-interacting protein 
Nucleophosmin 1 (Npm1) [134]. NPM1 is a multi-functional protein, with roles in 
ribosome biogenesis, genomic stability, histone chaperoning, protein 
stabilization, and transcriptional regulation, among many others [135]. We found 
that Npm1 also localizes to Hoxa9 and Meis1, with higher levels in the low-
expressing E2A-HLF transformed cells (Fig. 3.27A, B). Of note, while MLL fusion 
proteins express Hexim1 at levels similar to E2A-HLF-transformed cells, they 
express less Hexim2 and Npm1 (Fig. 3.27C).  Thus, the differences in Npm1 
levels found by ChIP-qPCR at the Hoxa9 and Meis1 loci may be due to 




Figure 3.27 HEXIM and NPM1 expression and localization in fusion transformed 
cell lines A) ChIP for HEXIM1 and NPM1 at Hoxa9. Schematics of Hoxa9 are 
depicted below the graphs, with red arrows indicating transcription start sites and 
black boxes indicating exons. HD is the homeodomain-encoding exon. B) 
Binding at coding region of Meis1. C) qPCR for expression of Hexim1, Hexim2, 
and Npm1 in the fusion-transformed cell lines normalized to Gapdh. 
 
We also analyzed Hexim1 and Npm1 localization in M1 cells that express 
the transforming domain of AF9 or a control fragment with the hypothesis that 
AF9 may hinder Hexim and Npm1 binding to the active locus. These experiments 
showed that the M1-AF9 C-term cells had approximately two-fold less Hexim1 and 
Npm1 at the Hoxa9 and Meis1 loci (Fig. 3.28A, B).  
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Figure 3.28 Hexim1 and Npm1 localization in M1-control and M1-AF9 C-term cell 
lines A) ChIP-qPCR for HEXIM1 and NPM1 at Hoxa9. Schematics of Hoxa9 are 
depicted below the graphs, with red arrows indicating transcription start sites and 
black boxes indicating exons. HD is the homeodomain-encoding exon. B) 
Binding at coding region of Meis1. 
 
Interestingly, MLL fusion protein-transformed cells are highly resistant to 
the chemical HMBA (Fig. 3.29A), which upregulates HEXIM expression and 
leads to the differentiation of myeloid leukemia cells [136]. It will be interesting to 
determine whether Hexim levels increase at Hoxa9 in HMBA-treated E2A-HLF 
cells and whether HMBA-treated MLL fusion protein-transformed cells are able to 
block this localization. The results obtained thus far indicate that MLL-ENL 
transformed cells avoid HMBA-induced Hexim upregulation at the transcriptional 
level, while MLL-AF9 and E2A-HLF-transformed cells have increased levels of 
Hexim1 or 2 in response to HMBA (Fig. 3.29B). All cell lines experience slight 
increases in Npm1 expression (Fig. 3.29B). Thus, this may be a system in which 
to test for localization of Npm1 and Hexim proteins to Hox and Meis loci. Forcing 
the expression of HEXIM1 and NPM1 by retroviral transduction in different 
hematopoietic cell lines is another approach to testing whether these proteins are 
 76 
recruited to Hoxa9 to inhibit transcription and if MLL fusion proteins block this 
recruitment. 
 
Figure 3.29 Sensitivity of fusion-transformed cell lines to HMBA A) Cell count 
after 48 (left) and 72 (middle) hour treatments with HMBA. Control DMSO 
treatment (right) was used to assess general sensitivity of the cell lines. B) 
Expression of Hexim1, Hexim2, Npm1, and Hoxa9 after 24 hour HMBA 
treatment. Data are normalized to U2 snRNA. 
 
We began to explore how Npm1 and Hexim localization are altered during 
changes in Hoxa9 expression in the LPS differentiation system. These 
preliminary results do not show changes in the levels of these proteins at the 
locus, but rather a possible change in the distribution that may impact Hoxa9 
expression (Fig. 3.30). Upon LPS treatment of E2A-HLF-transformed cells and 
Hoxa9 down-regulation, Npm1 and Hexim1 appear to occupy the coding region 
of the gene. In the MLL fusion transformed cells, which do not show decreases in 
Hoxa9 expression in response to LPS, Npm1 and Hexim1 appear to be confined 
to the promoter region. Thus, Npm1 and Hexim1 may exert their inhibitory 
functions on the elongation machinery, as would be expected from the role of 
pTEFb in transcriptional elongation. 
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Figure 3.30 Hexim and Npm1 expression and localization after 24 hours of LPS 
treatments A) ChIP for HEXIM1 and NPM1 at Hoxa9 Schematics of Hoxa9 are 
depicted below the graphs, with red arrows indicating transcription start sites and 
black boxes indicating exons. HD is the homeodomain-encoding exon. B) 
Expression of HEXIM1, HEXIM2, and Hoxa9 after LPS treatment. Data are 
normalized to Gapdh. 
 
Further studies show that NPM1 represses Hoxa9 expression. In 
luciferase reporter assays using 293 cell transfectants, NPM1 was shown to 
repress MLL-fusion protein-mediated transactivation (Fig. 3.31), and this effect 
was potentiated by co-transfection with HEXIM1. In addition, a mutant of NPM1, 
NPMC+, that localizes to the cytoplasm and sequesters HEXIM1 [134] leads to 
activation of Hoxa9 promoter activity. Importantly, NPMC+ is the most common 
mutation found in leukemia, present in one third of all adult leukemias, and it is 
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associated with the upregulation of HOX genes [137,138]. Thus, it appears that 
NPM1 may have important roles in directly regulating HOX expression.  
            
Figure 3.31 Effects of NPM1 and HEXIM1 on MLL fusion protein-mediated 
Hoxa9 activation Luciferase reporter assay expressing luciferase from a Hoxa9 
promoter after transfection with the plasmids indicated below. 
 
We moved into a hematopoietic system to test whether NPM1 and 
NPMC+ have effects on Hox expression and Hox-mediated leukemic 
transformation. Preliminary experiments show that MLL-AF9 loses its ability to 
form leukemic colonies from hematopoietic progenitor cells in the presence of 
NPM1 (Fig. 3.32). Whether this is due to NPM1’s direct antagonism of MLL-AF9 
remains to be seen.  
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Figure 3.32 NPM1 inhibition of MLL-AF9-mediated leukemogenesis Methyl 
cellulose cultures (left) showing MLL-AF9 loses its ability to form large, compact 
colonies in the presence of NPM (lower panel). Wright-Giemsa staining shows 
myeloblast that form after MLL-AF9 transduction and monocytic cells when NPM 
is co-transduced with MLL-AF9 (bottom right). 
 
Further, we tested whether the cytoplasmic mutant, NPMC+ could lead to 
leukemic transformation alone or in cooperation with another oncoprotein, FLT3-
ITD, which is commonly found in leukemias with NPMC+ [139]. The expression 
of NPMC+ alone in hematopoietic cells does lead to the activation of Hoxa9 (Fig. 
3.33), and this effect is enhanced by co-transduction with FLT3-ITD (Fig. 3.33). 
However, NPMC+ alone was not sufficient to lead to leukemic colony formation in 
methyl cellulose.  
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Figure 3.33 FLT3-ITD and NPM1 effects on Hoxa9 expression qPCR detection of 
Hoxa9 expression after one week of retroviral transduction with the constructs 
indicated along the x-axis. Results are expressed as fold difference over MSCV-
transduced cells. Data are normalized to Gapdh. 
 
Transduction with NPMC+ and FLT3-ITD did lead to the formation of very large, 
atypical colonies that exhibit high levels of Hoxa9 expression and uncontrolled 
cell growth. However, this phenotype does not appear to be due to the loss of 
NPM’s nuclear function as the phenotype was greatly potentiated by the 
combination of wild-type NPM1 and FLT3-ITD (Fig. 3.34)      
        
Figure 3.34 Morphology of hematopoietic cells co-transduced with FLT3-ITD and 
NPM1 Methyl cellulose colonies (left) show cohesive cells that develop after co-
transduction of NPM1 and FLT3-ITD. Wright-Giemsa staining reveals high 
nuclear to cytoplasmic ratio indicating that they may be neoplastic. 
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These cells do not appear to express hematopoietic lineage markers. It is 
possible that a non-hematopoietic cell was transformed to yield these colonies, or 
more provocatively, that a hematopoietic cell trans-differentiated into another cell 
type in response to the combination of FLT3-ITD and NPM1. These phenomena 
require more investigation to identify the cell type and the cell that it originated 
from. 
Redundancy in EAP  
Many of the interactions identified with AF9 raise the possibility of 
redundancy between subunits. There is structural and functional homology 
among, LAF4, AF5q31, and AF4, CYCLIN T1 and CYCLIN T2, and AF9 and 
ENL. One possibility is that they exist in distinct complexes, potentially at 
different target genes. The fact that we were never able to observe Cyclin T1 at 
Hoxa9 in murine or human leukemia cells may indicate that Cyclin T2 is the 
primary regulator of Hox genes.  
Similarly, relatively low levels of Af9 were detected at Hoxa9 and Meis1 in 
MLL-ENL transformed cells (Fig. 3.7), possibly suggesting that MLL-ENL does 
not require Af9 for transcriptional activation. Furthermore, Enl and AF9 were 
weakly identified as interacting proteins with AF9C-term and ENL, respectively 
(Table 3.3, [105]). It should be noted that, in these experiments, MLL-AF9 
appears to be a weaker oncogene than MLL-ENL with regards to Hoxa9 and 
Meis1 expression (Fig. 3.6) and RNA polymerase II-associated factors (Fig. 3.9). 
This may be due to the fact that MLL-AF9 is expressed at 25% the levels of MLL-
ENL (Fig. 3.35).            
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Figure 3.35 Expression of FLAG-MLL fusion proteins in MLL fusion transformed 
cells qPCR detection of MLL fusion proteins in fusion transformed cell lines 
priming FLAG sequence and N-terminal MLL sequence. Data are normalized to 
Gapdh. 
 
However, another possibility is that MLL-ENL, which contains most of the ENL 
protein, has a greater capacity to interact with positive regulators of transcription 
than the 90 C-terminal residues of AF9 found in the MLL-AF9 used in these 
experiments. For instance, MLL-ENL contains the histone binding YEATS 
domain that possibly aids in efficient targeting to loci, while MLL-AF9 lacks this 
domain. MLL-AF9 does recruit Enl to Hoxa9 and Meis1 (Fig. 3.7). Thus, in cases 
of MLL-rearranged leukemias, where much of AF9 or ENL may be lost from the 
translocation, there may be advantages to having both AF9 and ENL at target 
loci, and the importance of these proteins to each other, even given the weak 
association, has not been ruled out.  
A preliminary ChIP experiment indicates that both AF4 and AF5q31 are 
present at the Hoxa9 locus (Fig. 3.36). Thus, two or more of the FMR2 proteins 
may function together. In support of this, AF4 and AF5q31 were shown to 
preferentially heterodimerize through their C-terminal domains [100]. The precise 
role of these proteins remains to be defined. They do not appear to differ greatly 
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in their levels at Hoxa9 between the E2A-HLF and MLL fusion transformed cells. 
Thus, there may be differences in their ability to stimulate pTEFb activity [119] 
through some yet to be discovered mechanism that regulates FMR2 protein 
activity or associations. 
 
Figure 3.36 FMR2 family member binding at Hoxa9 Schematics of Hoxa9 are 
depicted below the graphs, with red arrows indicating transcription start sites and 
black boxes indicating exons. HD is the homeodomain-encoding exon. 
 
Hierarchy of EAP 
 
The hierarchy in EAP remains unclear. Thus far, data have been 
presented suggesting that pTEFb, in association with AF4 members and ENL, is 
sufficient for MLL fusion protein-mediated leukemogenesis, with other events 
such as Dot1L activity occurring downstream. Our differentiation experiments, 
which show the earliest and most dramatic dissociation of AF9, ENL, and Cyclin 
T2, lend support to this idea (Fig. 3.15). However, the order of downstream 
events that are critical to Hox activation and the different EAP subunits involved 







 MLL fusion proteins are multi-potent proteins that form a sophisticated 
transcriptional network,which leads to leukemia. Although there are many other 
aspects to the mechanism of MLL fusion protein-mediated leukemogenesis, 
several lines of evidence show that the fusion partner and its associating factors 
are critical. The work presented in this dissertation show the following: 
 The transforming domain of AF9 associates with other MLL fusion 
partners and enzymes associated with transcriptional elongation, including 
the CTD kinase pTEFb, and the HMT Dot1L, and this complex has been 
named Elongation Assisting Proteins (EAP). 
 EAP dissociates from target loci early in response to differentiation cues. 
 EAP remains bound at loci in the presence of MLL fusion proteins in spite 
of cues to differentiation. 
EAP components have also been identified in association with other MLL fusion 
partners, including AF4 and ENL, in independent studies [100,101,105,119]. A 
fascinating finding is that many of the nuclear fusion partners associate with each 
other, suggesting that they share a common mechanism of transformation. Even 
the cytoplasmic partners have been shown to recruit some of the same 
machinery as the nuclear partners albeit through an alternative mechanism [100]. 
This may greatly simplify therapeutic strategies of targeting MLL fusion protein 
 85 
associated leukemias, which are heterogeneous due to the variety of possible 
fusion partners.
The most effective therapeutic targets will be the proteins or associations 
that present the least amount of harm to normal cells. Unfortunately, MLL fusion 
proteins exploit transcription factors that are needed for the transcription of most 
genes. Thus, from the data presented to date, targeting aberrant protein-protein 
interactions in the MLL fusion protein-associated complexes, such as those with 
Dot1L and pTEFb, show the most promise. Another interesting approach would 
be to exploit the dual nature of EAP, which appears to be a bi-functional complex 
that contains transcriptional activators and repressors. Identifying signaling 
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